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Abstract
The desire to explain how synaptic plasticity arises from interactions between ions,
proteins and other signalling molecules has propelled the development of biophysical
models of molecular pathways in hippocampal, striatal and cerebellar synapses. The
experimental data underpinning such models is typically obtained from low-throughput,
hypothesis-driven experiments. We used high-throughput proteomic data and
bioinformatics datasets to assess the coverage of biophysical models.
To determine which molecules have been modelled, we surveyed biophysical models
of synaptic plasticity, identifying which proteins are involved in each model. We were
able to map 4.2% of previously reported synaptic proteins to entities in biophysical
models. Linking the modelled protein list to Gene Ontology terms shows that modelled
proteins are focused on functions such as calmodulin binding, cellular responses to
glucagon stimulus, G-alpha signalling and DARPP-32 events.
We cross-linked the set of modelled proteins with sets of genes associated with
common neurological diseases. We find some examples of disease-associated molecules
that are well represented in models, such as voltage-dependent calcium channel family
(CACNA1C ), dopamine D1 receptor, and glutamate ionotropic NMDA type 2A and 2B
receptors. Many other disease-associated genes have not been included in models of
synaptic plasticity, for example catechol-O-methyltransferase (COMT ) and MAOA. By
incorporating pathway enrichment results, we identify LAMTOR, a gene uniquely
associated with Schizophrenia, which is closely linked to the MAPK pathway found in
some models.
Our analysis provides a map of how molecular pathways underpinning neurological
diseases relate to synaptic biophysical models that can in turn be used to explore how
these molecular events might bridge scales into cellular processes and beyond. The map
illustrates disease areas where biophysical models have good coverage as well as domain
gaps that require significant further research.
Author summary
The 100 billion neurons in the human brain are connected by a billion trillion structures
called synapses. Each synapse contains hundreds of different proteins. Some proteins
sense the activity of the neurons connecting the synapse. Depending on what they sense,
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the proteins in the synapse are rearranged and new proteins are synthesised. This
changes how strongly the synapse influences its target neuron, and underlies learning
and memory. Scientists build computational models to reason about the complex
interactions between proteins. Here we list the proteins that have been included in
computational models to date. For good reasons, models do not always specify proteins
precisely, so to make the list we had to translate the names used for proteins in models
to gene names, which are used to identify proteins. Our translation could be used to
label computational models in the future. We found that the list of modelled proteins
contains only 4.2% of proteins associated with synapses, suggesting more proteins
should be added to models. We used lists of genes associated with neurological diseases
to suggest proteins to include in future models.
Introduction 1
Activity-dependent synaptic plasticity is necessary for learning and memory [1]. Since 2
the discovery of long term potentiation (LTP) and long term depression (LTD) [2,3], it 3
has been shown that synaptic plasticity can depend strongly on patterns of pre-and 4
post-synaptic firing [4] and neuromodulators [5]. Forms of plasticity vary between types 5
of synapses and brain region [4], which could be explained by the local proteome, 6
i.e. the expressed proteins and their abundances; PSD-95 knock-outs demonstrate the 7
influence of the proteome on synaptic plasticity [6]. Synaptic plasticity underlies 8
behaviour, as evidenced by the effect of antagonising NMDA receptors [1], and synaptic 9
proteins underlie disease [7]. 10
Synapses have been modelled computationally at various levels of detail. Models at a 11
phenomenological level, such as spike-timing dependent plasticity (STDP) models, link 12
firing patterns in the pre- and postsynaptic neurons to changes in synaptic strength 13
with little or no reference to the underlying molecules [8]. Biophysical models refer to at 14
least some known molecular actors in synaptic plasticity. In 2009 there were at least 117 15
biophysical postsynaptic signal transduction models [9] and the number is 16
growing [10,11]. 17
Recent advances in tissue and cell extraction techniques and sample processing allow 18
localised proteomes to be determined, e.g. the synapse including the smaller presynaptic 19
or postsynaptic proteomes [12,13]. The most recent analysis of 37 published synaptic 20
proteomic datasets contains 1,867 presynaptic genes, 5,053 postsynaptic genes and 5,862 21
synaptic genes (with human EntrezID identifiers) respectively. These numbers are large 22
compared to results from individual studies. Nevertheless, data inclusion was highly 23
restrictive and the augmented numbers can be partly explained by higher experimental 24
sensitivity and the broad use of high-throughput techniques (a manuscript containing 25
detailed analysis of the synaptic proteome is in preparation). 26
These synaptic protein lists make it possible to compare systematically proteins 27
contained in computational models of synapses with those proteins likely to be in the 28
synapse. In this paper we: (1) survey a selection of biophysical models of synaptic 29
plasticity, identifying which proteins are involved in each model, and describing the 30
complexity and detail of description of signalling pathways within the models; 31
(2) compare the proteins in models with synaptic protein lists, thus showing what 32
fraction of synaptic proteins have been considered in models; (3) identify the functional 33
classes of proteins in models; and (4) compare the proteins in models with those involved 34
in neurological diseases. This work should help inform what proteins and pathways 35
should be considered in new modelling efforts. While new datasets offer possibilities for 36
models of greater scope and detail, it is important to understand the foundations that 37
have been laid by existing computational models of synaptic plasticity, which we do 38
thematically before moving to the identification of proteins in models and the discussion 39
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of implications of our findings for future synaptic models and model annotation. 40
Biophysical models of synaptic plasticity 41
To set the scene for our analysis of proteins in biophysical models of synapses, we first 42
give an overview of how the questions addressed in models of synaptic plasticity have 43
shaped the development of simulation methods, and describe the main hippocampal, 44
striatal and cerebellar pathways that have been modelled. We categorise simulation 45
methods as non-spatial, spatial or multiscale and as deterministic or stochastic. Table 1 46
shows examples of simulation packages and associated studies that fall into each 47
category. Rather than using simulators, some studies use bespoke code in languages 48
such as Java, or generic mathematical environments such as MatLab. 49
Table 1. Overview of simulation environments.
Deterministic Stochastic
Non-spatial Berkeley Madonna 8.0 (BM8) [14]1
GENESIS [15]2
Java [16]3)
ode15s (SimBiology, MatLab
toolbox) [17,18]4
PLAS (Power Law Analysis and
Simulation) [19]5
Xcellarator (Mathematica) [20]6
XPPAUT [21,22]7
KaSim [23]8
StochSim [24]9
Spatial NEURON10
STEPS [25]11
Virtual Cell [26]12
MCell [27]13
NeuroRD [28–31]14
Smoldyn [32]15
STEPS [25]
Multiscale E-Cell 3 ode [33]16
NEURON + E-Cell 3 ode [34]
Simulation environments listed according to whether they support deterministic or
stochastic simulations, and non-spatial, spatial or multiscale simulations (ordered
alphabetically by simulator). URLs for the simulation environments are indicated by
superscripts (see below). References for studies using each simulation are given.
1http://www.berkeleymadonna.com/index.html 2http://www.genesis-sim.org/
3https://www.java.com/en/ 4http://uk.mathworks.com/products/simbiology/
5http://enzymology.fc.ul.pt/software/plas/ 6http://www.cellerator.info/
7http://www.math.pitt.edu/~bard/xpp/xpp.html
8https://github.com/Kappa-Dev/KaSim/
9https://sourceforge.net/projects/stochsim/
10https://www.neuron.yale.edu/neuron/
11http://steps.sourceforge.net/STEPS/default.php 12http://vcell.org/
13http://mcell.org/ 14http://krasnow1.gmu.edu/CENlab/software.html
15http://www.smoldyn.org/about2.html 16http://www.e-cell.org/.
Non-spatial models 50
Many of the simulation methods and issues associated with models of signalling 51
pathways are found in models of calcium/calmodulin dependent kinase II (CaMKII) 52
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and the intricate dynamics of its phosphorylation states and interactions with 53
calcium-bound calmodulin (CaM). 54
Mean field models of CaMKII In 1985 Lisman [35] advanced the hypothesis, 55
expressed as a mathematical model, that memories could be stored in bistable molecular 56
switches comprised of auto-phosphorylating kinases. Following the discoveries that 57
CaMKII is an autophosphorylating holoenzyme [36] and is a major component of the 58
postsynaptic density (PSD) [37], Lisman and Goldring [38] proposed that CaMKII 59
could form the basis for the auto-phosphorylating switch. Their ordinary differential 60
equations (ODEs) described how the probability of a CaMKII holoenzyme being “on” – 61
the “mean field” – could depend on the calcium concentration and the number of 62
phosphorylation sites required to switch the CaMKII holoenzyme on. Solving these 63
equations demonstrated that the number of CaMKII holoenzymes activated could 64
depend on the duration of the calcium stimulus, thus allowing CaMKII to act as graded 65
rather than binary switch. Furthermore, the time taken for the switch to turn on could 66
be modulated by changing the threshold number of sites that needed to be 67
phosphorylated before the holoenzyme entered an auto-phosphorylated state. 68
Analysis of mean field models Mean-field ODE models allow stability analysis to 69
be undertaken, which can show, for example, that a model of CaMKII has two stable 70
states – almost fully phosphorylated or almost fully dephosphorylated – within a wide 71
range of calcium concentrations [39]. Stability analysis has also been used to inform how 72
parameters should be set to give a biphasic calcium-synaptic strength curve, with LTD 73
at moderate concentrations of calcium and LTP at high concentrations [22]. 74
Stochastic models of CaMKII In a volume containing N reacting molecules of a 75
species, there will be fluctuations of the order of 1/
√
N in the concentration of the 76
species predicted by the mean-field solution. For large volumes it follows that stochastic 77
effects can be neglected, but in the ∼1 fl volume of the spine head the number of 78
CaMKII holoenzymes is considerably finite – an average of 30 are seen in electron 79
microscopy (EM) images of immunuogold labelled PSDs [40] – so there will be 80
significant variability between experiments in the same conditions. In order to 81
determine the accuracy of the encoded information for a given number of holoenzymes, 82
Lisman and Goldring [38] used the binomial formula to compute the mean and standard 83
deviation of the number of fully phosphorylated CaMKII holoenzymes, which suggested 84
that graded information could be stored to an accuracy of around 10%. 85
Rather than deriving variability from mean field simulations, stochastic 86
(“Monte-Carlo”) models can be built. Each run of a stochastic model is generated by 87
drawing random numbers to decide when bonds are made or broken, and when changes 88
in state occur; the variability of the model is obtained by analysing multiple runs. A 89
simple method to simulate chemical reactions accurately is Gillespie’s stochastic 90
simulation algorithm (SSA) [41], as used in some simulations [42]. 91
Combinatorial complexity in models of CaMKII One challenge in modelling 92
CaMKII is that each CaMKII holoenzyme comprises multiple subunits; initial estimates 93
were of 8–14 subunits, but EM and X-ray crystallography show that there are 12 94
subunits [43–45] arranged in two hexamer rings. Since a phosphorylated subunit can act 95
as a kinase to its neighbour, the multiple subunits give rise to a combinatorially large 96
number of meaningful configurations (states) of the holoenzyme. For example, a model 97
with 6 subunits, each of which can be in one of 12 states, can be in 498,004 98
configurations according to the necklace function [46] and would therefore need the 99
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same number of ODEs to simulate. To simulate the dodecamer ring would require 100
∼ 1012 states, an impractical number of states to model with ODEs. 101
This combinatorial problem can be alleviated by model simplification, for example 102
by (i) reducing the number of subunits to 4 and (ii) lumping together states that are 103
invariant to rotations and adjusting the reaction rates between states according to their 104
multiplicities [47]. These strategies are used in other deterministic and stochastic 105
models of CaMKII [22,48,49]. A further simplification can be made by lumping 106
together states with the same number of phosphorylated subunits, and weighting the 107
transition rates between these states [39]. 108
Agent-based simulation Combinatorial complexity can also be dealt with using 109
agent-based simulation, in which the states of individual molecules rather than 110
populations of molecules are followed through the simulation [50]. For example, in 111
simulations of a 10-subunit CaMKII holoenzyme [51], there was one variable per 112
subunit, each of which described which of 5 states the subunit was in. The state of each 113
holoenzyme was therefore described by 10 state variables, giving 976,887 states of the 114
holoenzyme. Transition probabilities between a subunit’s states depended on its own 115
state and that of its neighbouring subunit. Transitions were generated in 100 ms time 116
steps in each subunit in turn, based on the state of the holoenzyme in the previous time 117
step – similar to the τ -leap algorithm later formalised by Gillespie [52]. As this method 118
is based on a fixed time step it can be combined with deterministic simulation of some 119
elements of the system, as in a model of CaMKII activation in a dendritic spine [53]. 120
Rule-based simulation Agent-based simulation alone does not solve the problem of 121
how to represent the states and the transitions between states clearly and concisely [50]. 122
To specify transitions in agent-based simulations “rules” are specified in which the state 123
of a fragment of system is mapped to the transitions that can occur within that 124
fragment. For example a CaMKII monomer may be phosphorylated when both it and 125
its neighbour (the fragment) are bound to Ca2+-CaM complex [24]. The StochSim 126
agent-based simulator [54] describes rules by using flags to represent phosphorylation 127
and binding states to be attached to molecules. However, the StochSim description of 128
binding of CaM to CaMKII, phosphorylation states of CaM and trapping of CaM by 129
CaMKII [24] is, arguably, unwieldy, requiring 1,209 lines of code. 130
Second generation rule-based modelling languages such as Kappa [55] or BioNetGen 131
(BNGL, [56]) have a well-defined, general syntax to specify binding sites and states of 132
proteins and interactions between protein binding domains. The interaction rules can be 133
expanded to generate the “biological network”, i.e. the full set of complexes and 134
reactions needed to simulate the system [56]. These reactions can be converted into 135
ODEs or stochastic differential equations (SDEs), or simulated using a stochastic 136
simulation method [41,52]. In another approach – dubbed “Network Free” [56], since no 137
biological network is generated – simulators, such as KaSim [55] or NFSim [57], create 138
the complexes that exist throughout a simulation dynamically. Network-free methods 139
avoid the prohibitive memory requirements needed to store all possible states in a large 140
network [57], and even allow simulations with infinite numbers of potential species [55]. 141
This form of “on-the-fly” simulation is intrinsically stochastic, with transitions 142
occurring one rule at time, similar to Gillespie’s SSA [41]. For smaller networks, ODEs, 143
SDEs or the SSA are faster, but because the simulation speed of these methods scales 144
roughly with network size (i.e. the number of reactions), for larger networks these 145
conventional methods are slower than network-free simulation [57]. 146
Varying model structures Authors devise differing descriptions of the same 147
pathway. For example Byrne et al. [58], Stefan et al. [59] and Faas et al. [14] all describe 148
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the binding of calcium to CaM, but each model has a distinct structure. The models of 149
Byrne et al. and Faas et al. assume cooperativity within the N and C lobes of CaM: the 150
rate at which a calcium ion binds to a lobe with one calcium bound is different from the 151
rate at which calcium binds to the lobe in the apo, unliganded, state. In contrast, Stefan 152
et al. assume that the affinity of each of the four positions on CaM is independent, but 153
that these affinities depend on whether the entire CaM molecule in the “tense” or 154
“relaxed” conformation [60], which is an allosteric mechanism [61]. The two positions 155
within each lobe are assumed to be equivalent by Faas et al., but not by Byrne et al. 156
The model of Faas et al. has been fit against kinetic data, which is richer than the 157
binding curves fit by Byrne et al. and Stefan et al., but it has not been investigated 158
whether the parameters of these earlier models could be adjusted to fit the kinetic data. 159
There is also diversity in the number of states monomers in models of CaMKII may 160
assume, and how the multimeric structure of the molecule is represented. An additional 161
variation in particle-based simulations of CaMKII is that once the CaM N or C lobe is 162
bound to a CaMKII monomer, it becomes much more likely that the other lobe on the 163
same CaM molecule will bind to a neighbouring CaMKII monomer on the hexamer 164
ring [58]. This necessary to fit Ca-chelator-induced dissociation curves [62] and 165
steady-state CaM-CaMKII binding curves [43]. A result of this assumption is that the 166
rate of CaM binding to CaMKII is dominated by the more affine N-lobe. 167
Biophysical constraints on parameters A number of strategies are used to 168
reduce the considerable number of reaction coefficients in molecular models. For 169
example, the reactions in Byrne et al. [58] are parameterised by 2 sets of 24 parameters, 170
but the forward reaction coefficients are all set to be equal, reducing the number to 2 171
sets of 13. The principle of microscopic reversibility [61] is used to link reaction 172
coefficients that are in loops, taking the number down to 2 sets of 9. Microscopic 173
reversibility applies generally, though some ion channels are exceptions to this rule [61]. 174
Other linkages between parameters can be postulated; for example in the allosteric 175
model of Stefan et al. [59], the ratio between the affinities of each site for calcium in the 176
tense and relaxed conformations is assumed to be the same for each of the four sites. 177
Data used to constrain parameters Various types of data have been used to 178
constrain the parameters of single pathway models. To obtain equilibrium binding 179
curves, equilibrium dialysis with radioactively labelled ligands can be used, as by 180
Crouch and Klee in their determination of Ca2+-CaM binding. More recently, 181
stopped-flow fluometry [43] has been used for the same purpose. This method has the 182
disadvantage of a relatively long dead time of the order of 2 ms, which hinders 183
determining fast dynamics, e.g. of the N lobe of CaM. A faster method is calcium 184
uncaging, which can lead to a sub-0.1 ms change in calcium concentration, and 185
measurement with a fast fluorescent calcium indicator [14]. 186
Spectroscopic analysis can be used to infer conformational changes, e.g. the tense to 187
relaxed conformation change upon binding of a calcium ion to CaM [60]. 188
Phosphorylation states, e.g. of CaMKII, can be measured using radioactively labelled 189
ATP [43] which can be coupled with immunoprecipitation and gel electrophoresis [63]. 190
Optimisation of free parameters Even after reducing the number of parameters 191
there are typically a number of free parameters in a model, and a number of 192
optimisation techniques are used to fit them to data, for example particle swarm 193
optimisation [58]. Latin hypercube sampling can be used to determine global parameter 194
sensitivity [20]. 195
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Hypothesis-driven and simplified modelling In one combined 196
experimental-modelling study [63], the authors engineered a monomeric form of 197
CaMKII. This allowed them to measure the CaM-dependent phosphorylation properties 198
of CaMKII and produce a simplified computational model, which predicted that the 199
amount of CaMKII activation would depend on the frequency of a presented train of Ca 200
pulses: CaMKII could thus act as a frequency decoder. A number of CaMKII models at 201
various levels of detail have been formulated to explain the dependence of CaMKII 202
activation on the frequency of calcium pulses [47,48,64]. 203
Data-driven rule-based modelling Proteomic studies of the synapse (Table S2) 204
show that there are many proteins in the synapse not included in the models described 205
thus far. The challenges of combinatorial complexity, already encountered in models of 206
CaMKII, are magnified as more proteins are added. Rule-based modelling has been 207
applied to simulate a network containing 54 proteins, with interactions were described 208
by 136 rules [23]. This model makes predictions about the molecular composition of 209
complexes that could occur in the PSD. 210
Spatial models 211
The modelling methods described so far assume that molecules are within a well-stirred, 212
spatially homogeneous environment. However, the cellular environment is not 213
homogeneous; for example, calcium enters through N-methyl-O-aspartic acid 214
receptors (NMDARs) on one side of the spine head. It can react with buffers on a 215
shorter timescale than it takes to diffuse through the spine, and can exist within 216
microdomains around the NMDARs briefly at high concentrations. Thus, to address 217
some questions, it is necessary to model space explicitly. 218
Deterministic reaction-diffusion Deterministic diffusion is modelled by splitting 219
cellular space into compartments and formulating ODEs to describe how reactions 220
within compartments and fluxes between compartments affect the concentrations of 221
species within each compartment. Deterministic diffusion along one dimension has been 222
used in models of calcium and other intracellular signalling in spines [65–67]. Whilst 223
these models do not model LTP and LTD explicitly, they give insights such as that the 224
combination of calcium pumps and buffers can confine calcium and activated CaMKII 225
to the synaptic spine head [67], or that the temporal ordering of input at weak and 226
strong synapses with NMDARs determines the concentration of calcium in the spine, 227
which will then influence the intracellular pathways underlying LTP and LTD [66]. The 228
NEURON simulator, used widely in models of electrical activity of neurons, also 229
supports reaction-diffusion, with recent work to extend these capabilities [68]. 230
Deterministic reaction-diffusion can be simulated in 3D by splitting cellular space into 231
tetrahedral or cubic compartments, as implemented in the STEPS simulator [69]. 232
Compartmental stochastic reaction-diffusion The numbers of molecules in each 233
compartment of a mesh is often small enough to warrant stochastic simulation methods. 234
Gillespie’s SSA can be extended to a compartmentalised volume by replicating the set 235
reactants in each compartment, and treating diffusion of reactants between each 236
compartment as a type of reaction [41]. This “Spatial SSA” method and more efficient 237
approximations [70] have been used for a number of simulations of medium spiny 238
projection neurons in the striatum [28–31] and is implemented in the simulators 239
NeuroRD [28] and STEPS [69]. 240
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Compartmental agent-based stochastic reaction-diffusion The Spatial SSA 241
requires one variable in each compartment to describe the number of molecules in every 242
possible state in the system, and therefore is ill-adapted to deal with models of 243
molecules with many states, such as CaMKII. A custom extension to the Spatial SSA 244
has been used to study the relative effects of the stochastic opening and closing of 245
NMDARs and of stochastic binding between CaMKII holoenzymes and CaM in a spine 246
head [27]. The results showed that NMDARs were a greater source of noise, due to their 247
smaller numbers than the CaMKII holoenzymes. The agent-based, rule-based simulator 248
SpatialKappa [71] extends the Kappa language syntax and the KaSim algorithm to 249
allow diffusion of complexes between voxels in regular meshes. 250
Particle-based stochastic reaction-diffusion In particle-based simulation 251
methods, each molecule has a location in 3D space or on a 2D membrane and moves in 252
Brownian leaps. Reactions may occur when particles come within an interaction radius 253
of each other. Simulators implementing this method include MCell [72] and 254
Smoldyn [73]. MCell has been used to model diffusion of glutamate molecules in the 255
synaptic cleft and their binding to NMDARs and 256
α-amino-3-hydroxy-5-methyl-4-isoxalone propionic acid receptors (AMPARs) [27,74], 257
and influx of calcium into the spine head and its interaction with calcium binding 258
proteins [75,76]. The most recent version of Smoldyn supports the rule-based BNGL 259
language, but only to generate reaction networks, not to perform network-free 260
simulation. 261
Modelling diffusion measurements Khan et al. [32] used a spatial model built 262
with Smoldyn to interpret their fluorescence recovery after photo-bleach (FRAP) 263
measurements of CaMKII diffusing in a spine head before and after glutamatergic 264
stimulation. Eleven bidirectional reactions described binding of phosphorylated CaMKII 265
to the PSD, binding of non-phosphorylated CaMKII to the actin cytoskeleton, and 266
CaMKII self-aggregation. All these reactions contribute to keeping stable CaMKII 267
concentrations in stimulated spines, providing an explanation of sequestration of 268
CaMKII in dendritic spines. 269
Multiscale modelling It is possible to simulate reaction-diffusion and the membrane 270
potential using the same spatial mesh, but these simulations are likely to run very slowly 271
because of the unnecessarily fine mesh in parts of the model, such as the dendrites, 272
where concentration gradients are lower. Multiscale modelling, defined as the process of 273
using multiple models at different scales simultaneously to describe a system [77], can 274
allow for the desired level of detail with tractable simulation times. To demonstrate a 275
multiscale algorithm to integrate detailed models of signalling networks within electrical 276
models of neuron, Mattioni and Le Nove`re [34] used a model of a striatal medium spiny 277
projection neuron (MSPN) with 1,000 synaptic spines attached. The electrical activity 278
and calcium accumulation in the dendrites and soma of the neuron were simulated using 279
the NEURON implementation of the compartmental modelling method. Within each 280
spine, the calcium flux through AMPARs, NMDARs and voltage gated calcium 281
channels (VGCCs) calculated by the electrical model is fed to instances of a molecular 282
simulator (in this case E-CELL3), in which the calcium binds to CaM, which then 283
participates in a biochemical network typical of striatal MSPNs. A similar effort has 284
incorporated the rule-based SpatialKappa simulator into NEURON [78]. 285
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PP3
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mGluR/MAPK circuit CaMKII phosphorylation/dephosphorylation circuit
Fig 1. Partial block diagrams comparing essential elements of the
hippocampal biochemical circuit. Each small box represents an ion, monomer or
multimer. Red arrows indicate activating interactions. Blue lines ending in circles
represent inhibiting interactions. Within each box, the molecules can be one of
potentially many binding or phosphorylation states. The circuit is split into two
sub-circuits: the CaMKII phosphorylation/dephosphorylation circuit and the
mGluR/MAPK circuit.
Models of hippocampal synaptic signalling pathways 286
In tandem with the extensive experimental study of LTP and LTD in the hippocampus, 287
computational models of hippocampal synaptic plasticity have been developed. 288
The CaMKII phosphorylation-dephosphorylation circuit Lisman [79] 289
proposed a model to account for how LTP and LTD could be mediated by postsynaptic 290
calcium acting as a second messenger (Fig 1). A high concentration of calcium, caused 291
by coincident pre- and postsynaptic activity, leads, via binding to CaM, to 292
phosphorylation and then auto-phosphorylation of CaMKII. At moderate 293
concentrations calcium binds to calcineurin (PP3), which is also known as PP2B; we 294
use PP3 for consistency with gene identifiers. The calcineurin-calcium complex 295
dephosphorylates protein phosphatase inhibitor 1 (I1), thereby deactivating it. The 296
inactive I1 then unbinds from protein phosphatase 1 (PP1), allowing it to 297
dephosphorylate phosphorylated CaMKII. At high Ca2+ levels this pathway is 298
inhibited via Ca2+-CaM activated adenylate cyclase (AC), which then catalyses 299
production of cyclic adenosine monophosphate (cAMP) from adenosine 300
triphosphate (ATP). The cAMP then binds to the regulatory subunits of 301
cAMP-dependent protein kinase (PKA), releasing its catalytic subunits which then 302
phosphorylate I1, thereby allowing it to sequester PP1. The Ca2+-CaM complex also 303
activates phosphodiesterase (PDE), which hydrolises cAMP into adenosine 304
monophosphate (AMP), thus reducing the rate of activation of PKA. 305
Lisman formulated this biochemical circuit as a simplified steady-state mathematical 306
model of the net phosphorylation rate of CaMKII, and showed that a set of parameters 307
existed that would allow unphosphorylated (“off”) CaMKII molecules to be 308
phosphorylated (activated) by high Ca2+ levels, and phosphorylated (“on”) CaMKII 309
molecules to be dephosphorylated (inactivated) by low Ca2+ levels. Lisman 310
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hypothesised that, ultimately, CaMKII activation increases the non-NMDA component 311
of the synaptic response. The biochemical circuit of Lisman is included in a number of 312
dynamical biochemical models of postsynaptic signal transduction [80–84]. In some 313
cases PKA is assumed to be tonically active rather than released from inhibition by 314
cAMP, [83,85] and other features may be included such as sequestering of CaM by 315
neurogranin and SAP97 [83]. 316
AMPA receptor phosphorylation Models have been formulated in response to 317
the developing understanding of AMPARs [86]. AMPARs comprise four subunits, each 318
of which is one of GluR1–4. The phosphorylation at two sites on GluR1 affects the 319
function of the AMPAR multimer. In synapses in a “naive” state, i.e. those which have 320
not been exposed to any plasticity protocols, phosphorylation of Serine 831 (Ser831), by 321
CaMKII or protein kinase C (PKC), is associated with LTP [87,88] and 322
dephosphorylation of Serine 845 (Ser845) is associated with LTD [89]. In synapses that 323
have already experienced LTD, “dedepression” caused by a theta-burst stimulus is 324
associated with Ser845 phosphorylation, and in a synapse that has potentiated, the 325
Ser831 site is dephosphorylated during “depotentiation” [88]. 326
These findings led to the four state model of AMPARs by Castellani et al. [90], in 327
which potentiation is caused by phosphorylation of the Ser831 and Ser845 sites, and 328
LTD caused by dephosphorylation of the sites. The activation of the phosphatases and 329
kinases was set up in the model so that the phosphates were more activated than the 330
kinases at low concentrations, and vice-versa for high concentrations. Steady-state 331
analysis of the set of 4 bidirectional reactions gave a typical biphasic Ca2+-synaptic 332
strength curve in which there is LTD at moderate concentrations of calcium and LTP at 333
high concentrations. Furthermore, control of Ca2+ levels via adaptation of NMDARs 334
allowed modification of the threshold level of Ca2+ at which LTP rather than LTD 335
occurred, as in the Bienenstock-Cooper-Munro (BCM) rule [91]. 336
AMPAR trafficking Blocking AMPAR exocytosis causes run-down of synaptic 337
strengths, and inhibiting endocytosis of AMPARs causes an increase in AMPAR 338
responses [92]. This discovery lead to the idea of a stable distribution of receptors at the 339
synapse being replaced by a highly dynamic picture, with continuous exocytosis and 340
endocytosis of AMPARs [93]. The trafficking to synapses comprises three steps [94]: 341
(1) AMPARs bound to Transmembrane AMPA receptor regulatory protein (TARP) 342
proteins such as stargazin are inserted into the dendritic shaft or spine by 343
phosphorylation events caused by PKA, PKC, extracelluar regulated kinase (ERK) 344
(part of the mitogen-activated protein kinase (MAPK) family) or Phosphoinositide 345
3-kinase (PI3K), or myosin-V; (2) the AMPARs diffuse through the membrane to the 346
synapse; and (3) phosphorylation events (triggered by active CaMKII targeting 347
stargazin) increase the affinity of the AMPAR-stargazin complex for PDZ-containing 348
scaffolding proteins such as PSD95, PSD93, SAP97 and SAP102. AMPAR trafficking 349
away from synapses is thought to be an inverse process, whereby AMPARs are released 350
from PDZ proteins and diffuse from the synapse back to the dendrite, where they are 351
endocytosed. There is a link between trafficking and the phosphorylation states of 352
AMPARs, with phosphorylation of Ser845 on the GluR1 subunit needed to incorporate 353
GluR1 subunits into synapses [95], although it is not clear how strong this link is [96]. 354
Integrated modelling of CaMKII phosphorylation circuit and AMPAR 355
trafficking Urakubo et al. [84] explored whether a model that integrated AMPAR 356
trafficking with the CaMKII-phosphorylation-dephosphorylation biochemical circuit 357
first formulated by Lisman and implemented by Bhalla and Iyengar [80] could account 358
for spike-timing dependent plasticity (STDP). They embedded the circuit in a spine 359
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containing NMDARs, AMPARs and VGCCs in a simplified soma-and-dendrite 360
compartmental model with conductances used in models of CA1 hippocampal 361
cells [97, 98]. In their first model LTP resulted from pre-before-post spiking, but LTD 362
did not result from post-before-pre spiking. To cause LTD in this situation, it was 363
sufficient that the NMDARs were blocked by binding of Ca2+-bound CaM. This 364
biochemical detection circuit was linked to AMPAR phosphorylation and 365
dephosphorylation by the activities of the kinases CaMKII and PKA and the 366
phosphatases PP1, PP3 and protein phosphatase 2 (PP2) (commonly known as PP2A). 367
AMPAR trafficking was modelled by having four pools of AMPARs: (1) cytosolic; (2) in 368
the dendritic or spine shaft membrane; (3) at the synapse but not anchored by PDZ 369
proteins; and (4) at the synapse, anchored by PDZ proteins. The phosphorylated LTP 370
and LTD states were used to control the rates of endo- and exocytosis, and binding to 371
the PDZ proteins. 372
The MAPK circuit and metabotropic glutamate receptor (mGluR) 373
signalling To the CaMKII phosphorylation-dephosphorylation circuit the modular 374
model of Bhalla and Iyengar [80] adds the MAPK cascade, activated by mGluRs 375
(Fig 1). Input to mGluRs activates G-proteins, which then go on to activate 376
phospholipase C-β (PLC-β), leading to production of diacylglycerol (DAG) and 377
inositol (IP3) and phosphorylation of PKC. This activates the cascade of Ras, Raf, 378
mitogen-activated protein kinase kinase (MAP2K) and MAPK. In turn, MAPK 379
activates phospholipase A2 (PLA2), which cleaves arachidonic acid (AA) from 380
phospholipids. The AA binds to PKC, activating it, which in turn leads to more Ras 381
activity, completing the loop. The G-proteins also activate the 382
Ras–Raf–MAP2K–MAPK pathway via up-regulation of guanine exchange factor (GEF). 383
The parameters in the system were such that the persistent up-regulation of PKC was 384
enough to catalyse AC production in the CaMKII circuit, and thus up-regulate PKA 385
and down-regulate PP1, leading to prolonged CaMKII activation. There was also 386
inhibitory crosstalk from the CaMKII to the MAPK via inhibition of Raf by PKA. 387
Late LTP, synaptic tagging and gene expression The models described so far 388
all deal with the induction of early-LTP, which occurs up to 4 hours after induction and 389
does not depend on protein synthesis [99]. In contrast, late-LTP depends on protein and 390
mRNA synthesis. In order to solve the conundrum of how AMPAR proteins, which 391
were assumed not to be synthesised close to synapses, get to the synapses, Frey and 392
Morris [99] proposed that a “synaptic tag” is set when activity has potentiated the 393
synapse. Smolen et al. [100] formalised this concept into an ODE model containing four 394
pathways: (1) the MAPK cascade; (2) PKA activated by cAMP; (3) CaMKII; and 395
(4) Ca2+-activated calcium/calmodulin-dependent protein kinase kinase (CaMKK), 396
which activates calcium/calmodulin-dependent protein kinase (CaMKIV). The CaMKII, 397
MAPK, and PKA pathways are all required to set a synaptic tag. CaMKIV, assumed 398
to be in the nucleus, and MAPK are assumed to activate unknown transcription factors. 399
The input to the model was the assumed time courses of Ca2+, Raf and cAMP. The 400
CaMKII phosphorylation circuit was not modelled. 401
To induce late-LTP, translation and synaptic tags need to be active simultaneously. 402
Smolen et al. [16] devised a distinct model at a similar, relatively low, level of detail 403
containing notional synaptic LTP tags activated by Ca2+-CaM-CaMKII, LTD tags 404
activated by the Raf-MAPK pathway, local protein translation mediated by 405
autonomously active isoform of atypical protein kinase C ζ (PKMζ) (after a chequered 406
history, back in favour as a memory molecule [101]), and movement of PKMζ and 407
notional plasticity related proteins from the cytoplasm to synapses. The model was used 408
to explore how strong potentiating or depressing stimuli at one synapse can promote 409
PLOS 11/53
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/254094doi: bioRxiv preprint first posted online Jan. 28, 2018; 
Fig 2. Incomplete block diagrams comparing essential elements of striatal
biochemical circuit. Greyed nodes and edges denote shared elements with
hippocampal models. See Fig 1 for explanation.
protein synthesis that allows, at other synapses, weak stimuli to cause plasticity. 410
Models of striatal synaptic signalling pathways 411
The striatum integrates multiple inputs to the basal ganglia, such as glutamatergic 412
excitatory afferents from the cortex and dopaminergic inputs from the midbrain [102]. 413
Around 95% of striatal cells are MSPNs, in which signalling cascades activated 414
simultaneously by glutamatergic and dopaminergic stimuli is a necessary condition for 415
the LTP that underlies reinforcement learning [103]. Models of striatal MSPNs share 416
some pathways with hippocampal synapses and include striatum-specific proteins. 417
Multistate DARPP-32 An abundantly expressed protein in MSPNs is phosphatase 418
1 regulatory subunit 1B (PPP1R1B), known as dopamine- and cAMP-regulated 419
neuronal phosphoprotein with molecular weight 32 kDa (DARPP-32). As a homologue 420
of I1, it has the same major role of PP1 inhibition. It is a hub protein that is regulated 421
by multiple neurotransmitters and phosphorylation sites. There are at least 8 422
modification sites known in the DARPP-32 amino acid sequence, and 4 of them are 423
known to have a regulatory impact on DARPP-32 [104]. The threonine sites (Thr34 424
and Thr75, as positioned on the rat protein sequence) have a major regulatory role in 425
signal processing. Thr34 inhibits PP1 and is phosphorylated by PKA, which Thr75 426
inhibits. The serine sites (Ser137, Ser102, as positioned on the rat protein sequence) 427
regulate Thr34 positively. Ser137 inhibits dephosphorylation of Thr34 on Ca2+ 428
stimulation and Ser102 enhances phosphorylation of Thr34. A number of models of 429
dopamine (DA) and Ca2+ signal integration have included only Thr34 and Thr75 as 430
major switching factors between LTP and LTD [17,18,29,105]. A few models 431
incorporate all four phosphorylation sites [19,106]. 432
Glutamatergic and dopaminergic signal integration Lindskog et al. [105] 433
created an ODE model of interacting cascades activated by DA and Glutamate (Glu) 434
signals stimulating dopamine receptor D1 (DRD1) and Ca2+ influx through NMDAR, 435
respectively. The glutamatergic signalling cascade shares the general network structure 436
of the CaMKII circuit with hippocampal models (Fig 2), with a few major differences. 437
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Firstly, the inhibition of PP1 does not occur via I1 but rather via DARPP-32 438
phosphorylated at Thr34. Secondly, as the DRD1 is a G-protein-coupled 439
receptor (GPCR), DA input adds to the network G-protein activation events. On DA 440
stimulation, Gαβγ dissociates into Gα,olf and Gβγ subunits. Subsequently, Gα,olf binds 441
to AC and ATP, synthesising cAMP. The last event, which results in activation of 442
PKA and the cascade inhibiting PP1, is shared by both hippocampal and striatal 443
models. However, in contrast to hippocampal models, in Lindskog’s model [105], Ca2+ 444
inhibits AC, leaving its activation to DA input. Furthermore, Ca2+-activated PP3 445
dephosphorylates Thr34 counteracting the DA, but not the Ca2+ signal. 446
In the model Thr34 is both activated and inhibited by a Ca2+ feedforward signal, 447
which is conveyed by the PKA–PP2–Thr75 double negative feedback loop. PP2 448
dephosphorylates Thr75 but its action is enhanced by Ca2+ and PKA. The model 449
showed that the loop does not exclusively reinforce PKA pathway stimulated by DA but 450
instead acts as a competitive inhibitor for PKA. 451
The detailed model of Nakano et al. [15] demonstrated that the loop can have a 452
major role in LTP induction. They extended the network upstream of DARPP-32 and 453
added AMPAR phosphorylation and trafficking as a direct readout of plasticity. Their 454
model required activation of both CaMKII and PKA to reach striatal LTP. They also 455
included the downstream pathway of mGluR activation that represented mainly the 456
bi-directional effect of Ca2+ on IP3 receptor located at the endoplasmic reticulum. 457
STEP-mediated crosstalk between glutamatergic and dopaminergic 458
signalling cascades Gutierrez-Arenas et al. [18] developed a signalling model of two 459
main signalling pathways activated by DA and Glu inputs in MSPNs: AC–cAMP–PKA 460
and NMDAR–Ca2+–Ras. The AC-pathway was built on the model of Lindskog [105] by 461
adding a NMDAR-cascade, in which the dissociated Gβγ subunits activate Fyn which 462
phosphorylates a NMDAR subunit, thus enhancing the Ca2+ influx. Ca2+ activates the 463
MAPK pathway phosphorylating mitogen-activated protein kinase 1, also known as 464
ERK2 (MAPK1) at two sites. In striatal plasticity, MAPK1 activation is known to 465
require both DRD1 and NMDAR stimulation, as shown by the negative impact on 466
MAPK1 phosphorylation in the DARPP-32-knockout mouse model [107]. DRD1 467
activation by the DA-signal also enhanced the Ca2+ current through NMDAR, e.g. by 468
the phosphorylation of NMDAR by activated PKA. This particular reaction network 469
was chosen to allow for examination of various scenarios that could explain the results 470
of behavioural experiments showing distinctive segregation of behaviours of two animal 471
types representing Gα,olf -deficiency and DRD1-deficiency. The former exhibited 472
disruption of phosphorylation of the GluR1 subunit of AMPAR and the latter disrupted 473
phosphorylation of MAPK1 after acute psychostimulant administration. This effect was 474
present despite known crosstalks between two cascades mediated by striatal enriched 475
tyrosine phosphatase (STEP), which could balance the sensitivity in both pathways. 476
The model reproduced the segregation with an assumption that there are two 477
DRD1/Golf signalling compartments for each pathway distributed from common pools 478
of DRD1 and Golf . These compartments differ in DRD1 and Golf distribution 479
determined by the opposite affinity strengths for these molecules in each compartment. 480
These settings resulted in a competition between the two compartments for Golf/DRD1 481
resources, giving a ‘winning hand’ to the one with a stronger affinity to a given molecule. 482
Interactions between G-protein-coupled receptors DRD1 is a subfamily of 483
dopamine receptors and one of multiple types of GPCRs expressed in MSPNs, including 484
serotonin (5-HT2C receptor [108]), noradrenaline (α2-adrenoceptor, 485
β1-adrenoceptor [109], acetylcholine (muscarinic M4 receptor; M4R), adenosine (A2a 486
receptors; A2aR) and dopamine receptors of D2-like family. The last three, alongside 487
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DRD1, were modelled by Nair et al. [17], who simulated the reward prediction error 488
(defined as the difference between the received and expected reward). They modelled 489
two types of MSPNs, expressing either DRD1 and M4R (striatonigral projections) or 490
DRD2 and A2aR (striatopallidal projections). These two types of neurons process 491
DA-signals in two opposing manners by stimulating (DRD1-expressing) or inhibiting 492
(DRD2-expressing) the signalling cascade resulting in phosphorylation of DARPP-32 at 493
Thr34. In both models neuromodulators interact through Gi/o and Golf signalling, 494
inhibiting and activating AC5 respectively. Also in both models, AC5 is inhibited by 495
Gi/o at the basal state. In the DRD1-expressing neurons, Gi/o is coupled with the 496
M4R–tonic ACh signal; and in the DRD2-type of neurons with the DRD2–tonic DA 497
signal. In DRD1-neurons, the high PKA activation level was achieved with a 498
simultaneous DA-peak and ACh-dip. These neurotransmitter signals realise an 499
AND-gate, sensitive but noise-prone to a positive reward. In DRD2-neurons it is the 500
DA-dip that increases the PKA activation, even without Adn signal. This suggests that 501
in this type of neurons the cAMP–PKA cascade mainly detects reward omission. 502
Spatial specificity in synaptic plasticity The model of Oliveira et al. [29] 503
studied the mechanisms of spatial restriction of PKA activation by A-kinase anchoring 504
protein (AKAP). The problem required a multi-compartmental stochastic 505
reaction-diffusion approach. To evaluate distinct functions of anchoring, the 506
experimental protocol consisted of four spatial variations in localisation of AC and 507
PKA, either locating them in the spine head or at dendritic submembrane area. The 508
signalling network was adopted from Lindskog [105] and the stimulating signal was 509
either dopamine alone, corresponding to the reward response, or the combined DA and 510
Ca2+ influx used for LTP protocols. The results showed that for the induction of LTP 511
the colocalisation of PKA near the source of cAMP is more important than its 512
colocalisation near its target substrates (e.g. DARPP-32, PP2, PDE). 513
Kim et al. [31] used the NeuroRD algorithm to model 19 molecules in the 514
postsynaptic signalling pathways of the dendrites of striatal MSPNs with multiple 515
spines. The model investigated the hypothesis that temporal patterns, linked to Ca2+, 516
determine LTP or LTD induction, via PKC or endocannabinoid 517
2-arachidonoyl-glycerol (2AG) production respectively. The ratio between the number 518
of activated PKC and 2AG molecules was used as an indicator of the direction of 519
plasticity. It describes Gq-coupled pathways, the temporal pattern of Ca
2+ stimulation 520
and Gα,q activation. In the simulations LTP was specific to spines, whereas LTD was 521
more diffuse. This suggested that spatiotemporal control of striatal information 522
processing uses Gq-coupled pathways for decision-making. 523
Cerebellar synaptic models 524
Despite the historical importance of cerebellar granule cell to Purkinje cell plasticity, at 525
least 9 types of synaptic and non-synaptic plasticity are known [110]. The classical LTD 526
at cerebellar granule cell to Purkinje cell synapses occurs when there is simultaneous 527
climbing fibre and granule cell (parallel fibre) firing. At the heart of the model of 528
Kuroda et al. [111] is the MAPK positive feedback loop found in hippocampal and 529
striatal models [18,80], which here comprises Raf–MAP2K–MAPK-PLA2–AA–PKC. 530
Parallel fibre activity both activates and inhibits the loop. Parallel fibre glutamatergic 531
input to AMPARs causes Na+ influx, which triggers the Na+/Ca2+ exchanger causing 532
Ca2+ influx which, in turn, activates PKC and PLA2. PKC is also activated via 533
mGluR and AMPARs also activates Lyn tyrosine kinase directly, which activates Raf in 534
the MAPK loop. Parallel fibre input also releases NO, which, via the guanylate 535
cyclase–cGMP–PKG pathway, activates PP2, which inhibits MAP2K. Climbing fibre 536
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inputs also activate the MAPK link via Ca2+, and via Raf which is activated 537
corticotropin releasing hormone receptors (CRHR) activated by corticotropin releasing 538
factor. When the loop is active, activated PKC phosphorylates AMPARs, but in 539
contrast to hippocampal models phosphorylated AMPARs are internalised, leading to 540
LTD. 541
Antunes and DeSchutter [112] model LTD in cerebellar granule cell to Purkinje cell 542
synapses in the cerebellum using Gillespie’s SSA, as implemented in the STEPS 543
simulator. The model includes a version of the PKC-MAPK circuit (Fig 2), but with an 544
undetermined “Raf-activator” between PKC and Raf. This Raf-activator could be Ras 545
itself or indirect activation of Ras via complex Src/Proline-Rich Tyrosine Kinase 2 546
(PYK2). PP5 tonically inhibits Raf and MKP (DUSP) inhibits MAPK. Activated PKC 547
promotes endocytosis of AMPARs, thus causing LTD. The stochastic nature of the 548
model leads to LTD being stochastic and binary at individual synapses, but over the 549
ensemble of synapses this results in a graded relationship with the magnitude of the 550
activating Ca2+ signal. Increasing the number of molecules makes the system less 551
stochastic, and makes the resulting macroscopic signal less graded. 552
Antunes et al. [42] extend this model by incorporating CaMKII and PP3 to 553
implement LTP. They use the rule-based BioNetGen system to generate stochastic 554
reactions that are simulated using Gillespie’s SSA. In contrast to hippocampal models, 555
calcineurin promotes LTP by preventing endocytosis of AMPARs. RKIP is also 556
incorporated as an additional activator of Raf. 557
Summary 558
In summary, the development of biophysical models of synaptic plasticity has been 559
propelled by: (1) hypothesis-driven physiological and molecular biological discoveries; 560
(2) the need to formalise informally expressed hypotheses; (3) the intrinsic fascination 561
and intellectual challenge of complex biomolecules such as CaMKII; and (4) increasing 562
compute power, which makes it practical to model stochastic and spatial aspects of 563
synaptic signalling cascades. Challenges in the field have included dealing with 564
combinatorial complexity and finding appropriate sets of parameters. Recent 565
computational modelling methods, such as agent-based and particle based simulation, 566
address the problem of computational complexity. Depspite being an active field of 567
research, the perennial problem of inferring parameter values remains more intractable. 568
Analysis of proteins in synaptic models 569
Computational models of synaptic plasticity are important tools for understanding 570
synaptic and neural function. When they include molecular entities and phenomena 571
they can also be used to study dysfunction, and potentially model pharmacological 572
interventions. Clearly the coverage of synaptic molecules found in the existing ‘model 573
space’ is going to be very incomplete given the intense amount of effort required to 574
develop each model but here we sought to explore systematically molecular coverage to 575
identify significant gaps that might offer new opportunities. 576
Computational models contain a diverse cast of players, including proteins, second 577
messengers, reporters, ions and others. Models vary in how precisely they specify 578
proteins; for example Bhalla and Iyengar [80] specify AC1, AC2 and AC8, whereas 579
Castellani et al. [82] and Oliveira et al. [28] specify AC, which could, in principle, map 580
to any of the adenylate cyclases expressed in the synapse. This presents a problem when 581
mapping models to molecular identifiers, which we addressed by developing a mapping 582
from what we refer to as model “entities” to gene families. For example a protein such 583
as Calmodulin 1 can be mapped onto a single gene (CALM1 ), but a family of proteins 584
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such as metabotropic glutamate receptors maps onto more than one gene 585
(GRM1–GRM8 ). By definition, second messengers or ions do not map onto gene 586
symbols. 587
The concept of entities allows each model’s constituents to be catalogued faithfully 588
and then mapped onto identifiers according to the steps shown in Fig 3: (1) select 589
models to analyse; (2) determine all entities (e.g. proteins, protein multimers or families, 590
ions and second messengers) that are contained in each model; (3) map these entities 591
onto gene identifiers and higher level families; and (4) use the lists of entities in each 592
model and the mappings to undertake comparative analyses. These analyses include: 593
comparison of modelled proteins with pre- and postsynaptic proteomic datasets; 594
identification of properties of modelled genes, in particular cellular pathways, gene 595
ontology terms and disease; and comparison of models with each other. 596
List of entities in model
ID   TYPE
AC1  PROTEIN
AC8  PROTEIN
PDE4 PROTEIN_FAMILY
Ca   ION
Model 
Comparison
(Fig. 11)
Gene Ontology 
and Pathway 
Enrichment
(Figs. 7, 8 & 9)
Mapping of entities 
to HGNC gene 
symbols 
(Tabs. 11, 13 & 14)
(Fig. 5)
ID   GENE SYMB.
AC1  ADCY1
AC8  ADCY8
PDE4 PDE4A
PDE4 PDE4B
PDE4 PDE4C
PDE4 PDE4D
Ca   NA
MAPK NA
List of
gene symbols 
corresponding 
to model 
entities
GENE SYMB.
ADCY1
ADCY8
PDE4A
PDE4B
PDE4C
PDE4D
Manual and 
semi-
automatic 
curation
Model paper or 
code 
Mapping of entities 
to entity families 
(Tab. 13)
ID   FAMILY
AC1  AC
AC8  AC
PDE4 PDE
Ca   NA
List of entity 
families in 
model
FAMILY
AC
PDE
Comparison 
with disease 
genes
(Fig. 9, 
Tabs. 6 & 10)
Model Comparison & 
clustering
(Figs. 4, 11 & 12,
Tab. 4)
Fig 3. Overview of the modelling paper analysis process. Sets of data are shown in boxes with black rectangular
borders. Processes are shown in boxes with blue backgrounds and curved corners. Final analyses are shown in boxes with
dashed borders. “ID” refers to the modelled entity. Boldface type refers to column headers.
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Selection of models 597
We selected a number of published computational, biophysical models of synaptic 598
plasticity or related pathways (Table 3). Models that we regarded as phenomenological 599
or descriptive, i.e. models describing a function with no explicit reference to an 600
underlying mechanism, were excluded. For example, models of spike-timing dependent 601
synaptic plasticity are phenomenological, since they contain an empirical function that 602
maps spike times onto changes in plasticity with no reference to proteins. 603
The process of identifying the model constituents can be time-consuming, especially 604
when machine-readable descriptions are not available. In order to address our questions 605
regarding the molecular coverage of synaptic models, it sufficed to select a set of models 606
that we were reasonably confident gave good genetic coverage, rather than to identify 607
entities in every model. We assessed molecular coverage of pre-2010 models from the 608
tables in Manninen et al. [9] and we screened models published between 2010 and 609
December 31st 2015. 610
Sources of models 611
A number of the models we selected are written in standardised modelling languages and 612
hosted in large scale repositories such as ModelDB [113], BioModels [114], DOQCS [115] 613
and the CellML repository [116]. ModelDB is a curated database of computational 614
neuroscience models at the molecular and electrophysiological levels, written in a 615
number of languages. BioModels hosts models which focus on biochemical and cellular 616
systems at the physiological and biochemical levels, unrestricted by the biological 617
subject [114,117]. In the curated branch of BioModels, models have to be annotated 618
according to the minimal information requested in the annotation of biochemical 619
models (MIRIAM) standard [118], thus meaning that model constituents are mapped to 620
external identifiers. CellML is both a model format and a repository. The repository 621
hosts a wide range of biological models, which have documentation pages generated 622
from the meta-data supplied by model authors. DOQCS (Database of Quantitative Cell 623
Signalling) is a database tailored for storing chemical kinetics and reaction level 624
information [115]. The chemical-level description of each model corresponds to the 625
GENESIS/Kinetikit simulator and reflects reaction diagrams or ODE equations. 626
Table 2 summarises the numbers of models we analysed that are stored in 627
repositories and other locations, and the format of the model descriptions. Three of the 628
7 models deposited in the BioModels database were curated to MIRIAM standards. 629
Around half of all catalogued models (14) had non-machine readable descriptions. 630
Models in this group are often difficult to explore and extract information proves 631
challenging. There were 18 machine-readable models available from publication 632
attachments, on institute or lab servers and the four public modelling databases; some 633
models are deposited in more than one database. With two exceptions models were not 634
duplicated in ModelDB and BioModels; the Bhalla and Iyengar [80] model was present 635
in all four public modelling databases, and the Nakano et al. [15] model was found in 636
ModelDB and BioModels. We did not test the functionality or reproducibility of models; 637
only the availability and relative ease of exploration was examined. 638
Features of models 639
We extracted a number of features from each model to highlight their similarities and 640
differences (see Table 3). To quantify the model size, we counted the number of entities 641
that appear in the model. We also extracted information on numbers of dynamic 642
variables per compartment (“Vars/comp.”). Variables are values describing quantities 643
that change in the model. A compartment is defined as a spatial subsection within the 644
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Table 2. Overview of locations of models and their formats.
Type Location Format Fraction
non-
machine-
readable
attached to publication
or within publication
content
appendix, doc, pdf, excel
or descriptions, reaction
diagrams, equations
14/30
attached to publication
software-specific
3/30
institutes, labs servers 3/30
public
modelling
databases
ModelDB any (software-specific):
NEURON, Python, C,
C++, GENESIS, Java,
Matlab, XPP, etc.
8/30
machine-
readable
BioModels all (automatically
translated): SBML,
CellML, VCML, XPP,
SciLab, Octave, BioPAX
7/30
CellML CellML 1/30
DOQCS GENESIS 2/30
Fractions refer to the number of models in the category relative to the total of
annotated models. Each machine-readable model can be part of several categories. See
text for details.
model. Since the number of compartments varies with the fineness of the spatial mesh 645
used, the number of variables scales with the number of compartments, but the number 646
of variables per compartment will be a constant, independent of the spatial 647
discretisation used to simulate the model. To provide a measure of model complexity, 648
we used the ratio of thethe number of variables per compartment and the number of 649
entities (“Vars./Comp./Entities”, Table 3). 650
For example, in a model of calcium binding to a buffer in a single compartment, 651
there are two entities: calcium (an ion) and the buffer (a protein). There are three 652
variables, namely the concentrations of free calcium, free buffer and calcium-buffer 653
complex. To model diffusion of calcium, buffer and calcium-buffer complex, space could 654
be divided into 100 compartments. The number of variables would then be 300, but the 655
number of variables per compartment would be 3. There would still only be two entities 656
in this model – calcium and the buffer – and the variables per compartment per entity 657
ratio would be 1.5. 658
A high ratio of variables per compartment to entities reflects a detailed description 659
of a small pathway. For example the model of Byrne et al. [58] – whose stochastic model 660
describes binding of calcium, calmodulin and CaMKII – has 82 variables per 661
compartment and 3 entities, making a ratio of 27.3. The 82 variables correspond to the 662
combinations of calcium bound to the N and C lobes of calmodulin and whether or not 663
these complexes are bound to CaMKII. Dealing with this complexity in the simulation 664
is achieved by using an agent-based Gillespie method (Section “Non-spatial models” in 665
“Biophysical models of synaptic plasticity”). Agent-based simulation also allows the more 666
extreme example of Zeng and Holmes [27], whose model of the Ca2+-CaM-CaMKII-PP3 667
pathway (with calbindin and neurogranin; 6 entities in total) has 14,296,081 possible 668
complexes (i.e. variables), making a ratio of 2,382,680 variables per compartment per 669
entity. At the other end of the spectrum, a low variable to entity ratio indicates larger 670
pathways with each interaction modelled in less detail. For example, the ODE-based 671
model of Bhalla and Iyengar [80], with 44 entities and approximately 100 variables per 672
compartment, has a ratio of 2.3 variables per compartment per entity. 673
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In Table 3 we also indicate the region or cell type the model applies to. 674
Hippocampal CA1 cells are most frequently modelled, followed by striatal MSPNs and 675
cerebellar Purkinje neurons. In some models the location is not specified. 676
Table 3. Summary of models.
Paper Vars./comp. Entities Vars./comp./
Entities
Region
Antunes and De Schutter (2012) [112] 103 19 5.4 Cereb. Purk.
Antunes et al. (2016) [42] 17 Cereb. Purk.
Bhalla and Iyengar (1999) [80] 100 42 2.4 Hipp. CA1 Pyr.
Byrne et al. (2009) [58] 82 3 27.3 Hipp. CA1 Pyr.
Castellani et al. (2001) [90] 36 5 7.2 Cortex**
Castellani et al. (2005) [82] 33 13 2.5 Ex. glut. syn.**
Graupner and Brunel (2007) [22] 16 5 3.2 Hipp. CA1 Pyr.
Gutierrez-Arenas et al. (2014) [18] 188 34 5.5 Striatal MSPN, D1R expressing
Hernjak et al. (2005) [26] 9 5 1.8 Cereb. Purk.
Khan et al. (2011) [32] 12 1 12.0 Hipp. CA1 Pyr.
Kim et al. (2010) [21] 54 18 3.0 Hipp. CA1 Pyr.
Kim et al. (2011) [30] 16 17 1.0 Hipp. CA1 Pyr.
Kim et al. (2013) [31] 10 18 0.6 Striatal MSPN, mGluR1
expressing
Ko¨tter (1994) [119] 12 striatal MSPN
Kuroda et al. (2001) [111] 20 Cereb. Purk.
Li et al. (2012) [33] 95 8 11.9 Generic excitatory spine
Mattioni and Le Nove`re (2013) [34] 13 9 1.4 Striatal MSPN
Miller et al. (2005) [49] 58 4 14.5 **
Nair et al. (2015) [17] 80 16 5.0 Striatal MSPN, D1R and D2R
expressing*
Nakano et al. (2010) [15] 189 28 6.8 Striatal MSPN, D1R expressing
Oliveira et al. (2010) [28] 31 9 3.4 HEK293 cells
Oliveira et al. (2012) [29] 113 28 4.0 Stratial MSPN
Pepke et al. (2010) [20] 156 3 52.0 **
Qi et al. (2010) [19] 115 13 8.8 Stratial MSPN
Smolen et al. (2006) [100] 23 9 2.6 Hipp. CA1 Pyr.
Smolen et al. (2012) [16] 14 6 2.4 Hipp. CA1 Pyr.
Sorokina et al. (2011) [23] 1, 000, 000 55 18, 181.8 Ext. glut. syn.
Stefan et al. (2008) [59] 49 3 16.3 **
Zeng and Holmes (2010) [27] 14, 296, 081 6 2, 382, 680.2 Hipp. DG
Zhabotinsky et al. (2006) [83] 58 11 5.3 Hipp. CA1 Pyr.
“Paper” refers to the analysed model. “Vars/comp.” is the number of molecular variables per compartment, a measure of the
complexity of the model; this was not assessed for all papers. “Entities” is the number of entities in the model, and
“Vars./Enties” is the ratio between the number of variables per compartment and the number of entities. This roughly
corresponds to the level of detail of the model. “Region” refers to the brain region or cell type where the model is situated (**
– no cell specified). Abbreviation: Cereb. Purk., cerebellar Purkinje cell; Ex. glut. syn., excitatory glutamatergic synapse;
Hipp. CA1 Pyr., hippocampal CA1 pyramidal cells; Hipp. DG, hippocampal dentate gyrus cell; MSPN, medium spiny
projection neuron; * – denotes that there is more than one model presented in a study and numbers in this table refer to the
one with the larger number of “Entities”.
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Table 4. Frequency of entity types found in models.
Type Frequency Examples
Ion 2 Magnesium, Calcium
Neurotransmitter 5 Adenosine, Dopamine
Others 2 ATP and PIP2, intermediates in the IP3/DAG pathway
Protein 95 Neurogranin
Protein family 52 calmodulin, which may correspond to one of calmodulin-1, calmodulin-2 or
calmodulin-3
Protein multimer 8 AMPA receptor, which comprises a tetramer of GluR1, GluR2, GluR3 and GluR4
proteins.
Reporter 1 AKAR3
Second messenger 8 GTP (Guanosine triphosphate) or cAMP (cyclic AMP).
Total 173
Identifying entities in models 677
To identify the entities in each model, the publication describing the model and, if 678
available, an electronic description of the model were examined by one of the authors. 679
For each entity, we recorded the name used in the model publication and our standard 680
entity identifier. Models do not always specify the entities involved precisely. We 681
discussed ambiguous cases together and erred on the side of not imputing the identity of 682
a protein; for example a “Plasticity related protein” [16] was not mapped to an entity 683
identifier. 684
We identified 178 distinct entities across the 30 catalogued models (see S1 Table for 685
full list). As well as an identifier, each entity has a long name and a type which can be 686
one of: “ion”, “neurotransmitter”, “others”, “protein”, “protein family”, “protein 687
multimer”, “reporter” or “second messenger”. Table 4 shows how many of each type of 688
entity were identified, and gives examples. The most frequent entity type is “protein”, 689
followed by “protein family” and then “protein multimer”. 690
The rationale for having three protein types – “proteins”, “protein families” and 691
“protein multimers” – was to allow us to record as precisely as possible what was meant 692
in each computational model. A “protein” is a specific protein e.g. neurogranin, 693
encoded by a specific gene (NRGN ), so it is unambiguous as to which gene is implied by 694
the model. The same gene may produce multiple isoforms due to gene duplicates or 695
alternate splicing. For example PRKCZ produces two isoforms, PKCζ and PKMζ [120]. 696
A “protein multimer” is a multiprotein complex, e.g. an AMPA receptor, which 697
comprises a tetramer of a selection of GluR1, GluR2, GluR3 and GluR4 proteins. In 698
this example, if the model only specified “AMPAR” there would be ambiguity about 699
which of the GluR1–4 subunits are implied by the model. Coding AMPAR as a “protein 700
multimer” allows this ambiguity to be recorded and resolved as desired. A “protein 701
family” is a protein from a family of proteins, e.g. calmodulin, which may correspond to 702
one of calmodulin-1, calmodulin-2 or calmodulin-3. Again, it is not clear which protein 703
is implied by the model, though later we will use information about the synaptic 704
proteome to narrow down the possibilities. “AKAR3” is the only entity that was 705
classified as a reporter [17]. The FLIM-AKAR reporter was included in the model to 706
reflect the experimental setup where it is used to measure PKA dynamics. “Ions”, 707
“neurotransmitters” and “second messengers” were assigned to individual classes. They 708
are not proteins, but carry out crucial functions in the cell. 709
ATP and PIP2, both intermediates in the IP3/DAG pathway were classified as 710
“other”. ATP itself can produce a second messenger and is often referred to as a 711
precursor or “coenzyme”. Similarly, PIP2 is frequently acting as a precursor of a second 712
messenger [31]. 713
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The full catalogue of all model entities for all models is shown in matrix form in 714
Fig 4. The models are ordered according to hierarchical clustering (Ward’s 2D method, 715
as implemented in R’s hclust function with the Ward.2D method). This catalogue is 716
the basis for the rest of the analysis. 717
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Fig 4. Matrix of entities in models. The occurrence of an entity in a model is
indicated by open circles. Entity IDs are staggered for readability.
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Mapping entities to gene identifiers 718
In order to compare synaptic models with the synaptic proteome, we needed to map 719
each protein entity onto the proteins to which it might correspond. The construction of 720
this mapping is shown in Fig 5. Based on common practice in bioinformatics we decided 721
to use HUGO Gene Nomenclature Committee (HGNC) gene symbols and NCBI Entrez 722
Gene IDs to identify proteins/genes. The one-to-one mapping from HGNC gene 723
symbols to NCBI human Entrez Gene IDs [121] allowed this approach. 724
As presented in Fig 5, entities of type “protein” were mapped directly to HGNC 725
gene symbols. Entities classified as “protein family” and “protein multimer” required an 726
intermediate mapping step. We searched for ontologies that could be used to identify as 727
many of these entities as possible and map them to HGNC gene symbols. After 728
thorough analysis of available bioinformatic resources (see Methods) we decided to use 729
HGNC gene families to map entities of type “protein family” and “protein multimer” to 730
genes. For each such entity, we tried to identify a corresponding HGNC gene family, 731
and used manual NCBI mapping (see Methods) to check if the genes contained in this 732
family seemed likely to be what was meant in the models. For example, we mapped the 733
entity “Dopamine receptors” (DRD) to the HGNC family “Dopamine receptors”, which 734
contains the genes DRD1, DRD2, DRD3, DRD4 and DRD5. Since this seemed a 735
reasonable set, we accepted the mapping. 736
For some entities no one HGNC family gave a reasonable set of proteins, but the 737
intersection between two or more families did. For example the genes corresponding to 738
SHANK, by which we mean the family of proteins encoded by SHANK1, SHANK2 and 739
SHANK3, may be selected from the gene families list by choosing all genes that are in 740
the “Ankyrin repeat domain containing” (ANKRD) and “PDZ domain containing” 741
(PDZ) gene families. When we could not find a corresponding HGNC family or a 742
combination of HGNC families, we constructed our own mapping (see Methods). Since 743
“ions”, “neurotransmitters”, “others”, “reporters” and “second messengers” are not 744
proteins, we excluded them from the mapping to gene names. 745
Once gene families corresponding to 61 ”protein families” and “protein multimers” 746
were identified we could map each family or multimer onto a set of genes (S3 Table and 747
S4 Table). 331 unique HGNC gene symbols were identified based on protein families 748
and multimers. The union of this set of symbols with the 96 genes mapped directly from 749
type “protein” in the “full set of HGNC gene symbols in models” dataset. It contains a 750
total of 386 HGNC gene symbols. A number of “protein families” mapped onto the 751
same genes; for example the families PDE and PDE1 both contain PDE1A and PDE1B. 752
Comparison with proteomic data 753
HGNC families are general gene classes and do not contain information about tissue 754
specificity or expression patterns. To identify proteins found in the synapse, we used a 755
meta-analysis of published proteomic datasets of the presynapse, postsynapse and 756
synaptosome that we are preparing for another publication. The individual references, 757
as of July 2017, can be found in S2 Table. 758
The synaptosome is the largest data subset and extracted from brain homogenate. 759
The term synaptosome refer to the complete presynaptic terminal including 760
mitochondria, synaptic vesicles and the postsynaptic membrane together with the 761
PSD [122,123]. The PSD is a tightly connected, dense region of the postsynaptic 762
membrane which hosts a number of different receptors and regulatory units. The 763
presynapse and postsynapse are subsets of the synaptosome, and can be separated 764
through experimental steps. 765
The union of these three datasets, which we refer to as the “synaptic proteome”, 766
comprises 6,706 genes and is based on data obtained from 37 publications and 39 767
PLOS 22/53
.CC-BY 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/254094doi: bioRxiv preprint first posted online Jan. 28, 2018; 
List of entities in model
ID TYPE
AC1  PROTEIN
AC8  PROTEIN
AKAR3 REPORTER
Ca   ION
Glu NEUROTRANSMITTER
GTP SECOND MESSENGER
MAPK PROTEIN_FAMILY
NMDAR PROTEIN_MULTIMER
PDE4 PROTEIN_FAMILY
PIP2 OTHERS
PP3 PROTEIN_MULTIMER
SHANK1 PROTEIN
Mapping of TYPE
PROTEIN_MULTIMER
ID Gene family (HGNC)
“one-of”
NMDAR Glutamate 
ionotropic receptor 
NMDA type subunits
PP3 Calcineurin
Mapping of TYPE
PROTEIN
ID Gene Symbol
AC1  ADCY1
AC8  ADCY8
SHANK1 SHANK1
excluded in further 
analysis
Mapping of TYPE
PROTEIN_FAMILY
ID Gene family (HGNC)
“part-of”
“contained by”
MAPK Mitogen-activated 
protein kinase
PDE4 Phosphodiesterase 4
Mapping of TYPE
ION
NEUROTRANSMITTER
REPORTER
SECOND MESSENGER
OTHERS
ID Gene SYMBOL
AKAR3 NA
Ca NA
Glu NA
GTP NA
PIP2 NA
Mapping of HGNC Gene family
Gene family Gene Symbol
Mitogen-activated MAPK1,MAPK3,
protein kinase MAPK4,MAPK6,
MAPK7,MAPK8,
MAPK9,MAPK10,
MAPK11,MAPK12,
MAPK13,MAPK14,
MAPK15
Phosphodiesterase 4 PDE4A,PDE4B,
PDE4C,PDE4D
Glutamate GRIN1,GRIN2A,
ionotropic receptor GRIN2B,GRIN2C
NMDA type subunits
,GRIN2D,GRIN3A,
GRIN3B
Calcineurin PPP3CA,PPP3CB,
PPP3CC,PPP3R1,
PPP3R2
FILTERING 
for genes 
expressed in 
the synapse
(IN.SYNAPSE vs 
OUT.SYNAPSE)
final gene symbol set
“genes in models”
Synaptic 
proteome
Gene Ontology 
and pathway 
enrichment
(Figs. 7 & 8)
Comparison with 
disease genes
(Fig. 9,
Tabs. 6, 7, 8 & 10)
Full set of HGNC 
gene symbols in 
models
Fig 5. Overview of entity to Gene Symbol mapping process. Sets of data are shown in boxes with black rectangular
borders. Mappings are shown in boxes with blue backgrounds and curved corners. Dashed lines indicate additional
information, and the key outcome is highlighted in a box with green background. Bold font refers to column headers.
datasets (data as of July 2017). The extracted proteome was used to filter the “full set 768
of HGNC Gene symbols in models” (see Fig 5 and “Identifying entities in models”). We 769
found that every “protein family” (S3 Table) and “protein multimer” (S4 Table) in our 770
list contains at least one gene overlapping with the synaptic proteome. Genes not 771
expressed in the synapse (“OUT SYNAPSE” in S3 Table and S4 Table) were excluded 772
from further analysis. This filtering step reduces the 331 genes in families to 239 HGNC 773
gene symbols. Together with directly mapped proteins this leaves us with 294 unique 774
HGNC gene symbols describing all mapped genes in models, where families and 775
multimers were screened for the presence in the synapse. From now on we refer to this 776
gene set as “genes in models” (see green box, Fig 5). 777
The overlap between the final set of “genes in models” and the synaptic proteome, 778
as well as its subsets (presynaptic, postsynaptic, and synaptosome) is visualised in the 779
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Venn diagram in Fig 6. It can be seen that 46% of “genes in models” (135 genes) are 780
found in all three synaptic proteome datasets. Significantly lower numbers are expressed 781
in individual sub-datasets. These are 3, 14 and 21 genes for the presynapse, postsynapse 782
and synaptosome respectively (representing 1.0%, 4.7% and 7.1% of genes in models). 783
When disregarding “genes in models” present in the intersection of all three datasets, 784
more modelled genes are found in the postsynapse or synaptosome (143 genes) than the 785
presynapse or synaptosome (27 genes). Thus, postsynaptic genes appear to be the most 786
highly modelled subset. However, relative to the total size of the respective proteomes, 787
only 5.1% of postsynaptic genes (258 “genes in models” out of 5,053 postsynaptic genes) 788
versus 7.6% of presynaptic genes (142 “genes in models” out of 1,867 presynaptic genes) 789
are represented in the models. 790
PostsynapticPresynaptic
Model
Synaptosome
1275
9
21
237
114
3
3
557
2864
14
108
32
1342
1
135
Fig 6. Relationships between the sets of genes in postsynaptic, presynaptic,
synaptosome datasets and the sets of genes possibly present in models.
Postsynaptic genes in red, presynaptic in blue, the synaptosome in purple and genes in
models in green. Numbers refer to the number of genes in each subset and shading
shows how many sets a region belongs to (white – none; red – all four). It can be seen
that the number of genes in the proteome but not included in models is an order of
magnitude bigger than the number of proteins included in models and the proteomic
datasets. There are only 9 genes (listed in Table 5) found in models and none of the
proteomic datasets.
Nine modelled genes, all of type “protein” are not present in the synaptic proteome 791
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datasets (see lower right of the circle in Fig 6). Further investigation shows evidence for 792
all of them being expressed in the synapse (Table 5), so these 9 genes remained in the 793
set of “genes in models”. These cases illustrate how proteomic datasets still seem to be 794
slightly incomplete. 795
Table 5. Proteins in models and not to be found in synaptic datasets.
Entity ID Gene Reason for inclusion
ADORA2A ADORA2A Adenosine A2a receptors (A2aR) are expressed with D2R receptors
[17]
CALM2 CALM2 Unpublished dataset
CHRM4 CHRM4 Muscarinic cholinergic receptor shown to be expressed in go-
nadotropin releasing hormone neurons [124]
CRH CRH Corticotropin-releasing factor, regulating the release of adrenocorti-
cotropin in synapses [125]
DRD1 DRD1 D1 subtype of the G-protein coupled dopamine receptor - the most
abundant in the central nervous system. [126] confirms the presence
in neurons.
DRD2 DRD2 D2 subtype of the G-protein coupled dopamine receptor. [126]
confirms the presence in neurons.
DUSP1 DUSP1 Model specifies that DUSP1 feedback loop occurs in the dendritic
shaft, the soma and the nucleus [18]
I-1 PPP1R1A Unpublished dataset
PPP2R3A PPP2R3A Preliminary studies suggest PPP2R3A is present in both cytoplasm
and nucleus of cells in the striatum [127]. PPP2R3A mediates
Ca2-dependent dephosphorylation at Thr-75 of DARPP-32 [127].
Enrichment analysis of modelled genes 796
After compiling the “genes in models” list, we related it to existing biological knowledge, 797
in the form of gene sets annotated with various biological categories, supplied through a 798
number of databases. Depending on each database’s focus, structured, controlled, and 799
descriptive terms are associated to each gene. As an example for this study, we chose to 800
use the following ontologies: Gene Ontology (GO) [128], REACTOME Pathway 801
Database (REACTOME) [129] and Disease Ontology (DO) [130]. Amongst these GO is 802
the largest and most commonly used ontology, classifying genes within domains 803
including Molecular Function, Biological Process and Cellular Compartment. We also 804
used REACTOME, a free and manually curated database in which genes are tagged 805
with terms representing biochemical reactions and pathways they are involved in. A 806
pathway is composed of one or more reactions or reaction-like events, such as binding, 807
complex formation, transport or polymerisation. 808
To relate “genes in models” to their associated diseases, we used the DO to provide 809
disease classifications. Multiple sources contain gene disease information. We used 810
annotations retrieved from the GeneRif [131], OMIM [132,133] and Ensemble 811
Variation [134] databases. Based on annotations in the different ontologies we aimed to 812
identify functionalities shared by the “genes in models”. The topONTO package 813
implemented in R [135] was used to undertake enrichment analysis (see Methods). 814
The results are summarised using word clouds to show significantly enriched terms, 815
based on GO annotations, describing Molecular Functions (Fig 7A) and Biological 816
Processs (Fig 7B) for our “genes in models”. It can be seen that a high number of 817
modelled genes are involved in molecular functions such as “G-protein 818
beta/gamma-subunit complex binding”, “G-protein beta/gamma-subunit complex 819
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binding”, “GTPase activity”, “calmodulin binding”, “3’,5’-cyclic-AMP 820
phosphodiesterase activity”, “high voltage-gated calcium channel activity”, “signal 821
transducer activity” and “calcium-transporting ATPase activity” amongst others. The 822
most common biological processes are “cellular response to glucagon stimulus”, “platelet 823
activation”, “calcium ion transmembrane transport”, and “activation of protein kinase 824
A activity”. 825
A B
Fig 7. GO enrichment analysis results for “genes in models”. A: Molecular
Function ontology terms enriched for “genes in models”. B: Biological Process ontology
terms enriched for “genes in models”. The synaptic proteome was used as a background
dataset. The list of significant terms was obtained with the Fisher’s exact test and the
elim algorithm, followed by Benjamini and Yekutieli multiple testing correction. The
terms shown in clouds scored less than 0.01 p-value after the correction. Font size is
proportional to the term significance.
The identified molecular functions show that genes included in annotated models 826
cover key synaptic processes mainly concentrating around energy production as well as 827
synaptic signalling and information transmission. Identified biological processes are 828
slightly more diverse. Fairly generic processes were identified, showing that the set of 829
modelled genes covers these functions in the synapse. More unique processes appear 830
indicating the synapse specific biological processes described by genes in models. 831
Fig 8 shows results of the REACTOME enrichment analysis that identified “G 832
alpha (s) signalling events”, “G alpha (z) signalling events” and “DARPP-32 events” as 833
the top enriched pathways. The first two terms are parallel to each other on the 834
pathway hierarchy and have a common parent term of “GPCR downstream signalling”. 835
A comparison of the remaining members of this pathway with the enrichment results 836
shows that they are all significantly enriched in terms of our “genes in models”. The 837
identification of signalling pathways highlights a focus of the analysed models indicating 838
the central role of G-protein signalling. 839
When considering common diseases amongst “genes in models”, Fig 9A shows a 840
significant enrichment of “schizophrenia” associated genes in the set of “genes in 841
models”, followed by “bipolar disorder”, “Huntington’s disease” and “Alzheimer’s 842
Disease”. The order of results is slightly rearranged when considering the whole cell as a 843
background dataset (Fig 9B). For instance, “Alzheimer’s Disease” becomes more 844
prominent, showing the second highest significance for enrichment in our dataset of 845
interest. On the other hand, “bipolar disorders” drops down the list to the fifth position 846
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Fig 8. REACTOME enrichment analysis results for “genes in models”. The
synaptic proteome was used as background dataset. The list of significant terms was
obtained with the Fisher’s exact test and the elim algorithm, followed by Benjamini
and Yekutieli multiple testing correction. The terms shown in clouds scored less than
0.01 p-value after the correction.
A B
Fig 9. DO enrichment analysis results of “genes in models”. Two background
datasets were used: synaptic proteome (A) and all human protein coding genes (B).
The list of significant terms was obtained with the Fisher’s exact test and the elim
algorithm, followed by Benjamini and Yekutieli multiple testing correction. The terms
shown in clouds scored less than 0.01 p-value after the correction.
and “autistic disorder” appears in the results. This shows how different diseases not 847
only affect specific tissues but can affect a larger number of body regions inducing their 848
effect. 849
Modelled genes and their overlap with disease genes 850
Based on the preceding enrichment analyses we wanted to test for specific associations 851
of modelled genes with disease. Since synapses play a crucial role in signal transduction 852
and are affected in many neurological diseases, these were addressed in more detail. We 853
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picked seven representative examples of neurological disorders, 6 of which were based on 854
a list published by the Genes 2 Cognition online initiative: Attention Deficit 855
Hyperactivity Disorder (ADHD), Alzheimer’s Disease (AD), Autism, Bipolar Disorder 856
(BD), Depression and Schizophrenia. The seventh example was Parkinson’s Disease 857
(PD), motivated by our research interests. The list is a representative rather than 858
exhaustive sample of diseases affecting synapses, including diseases of mental health, 859
developmental disorders, as well as diseases of anatomical entity, such as 860
neurodegenerative diseases. Table 6 gives the DO identifiers and short descriptions of 861
each disease. 862
Table 6. Diseases of Interest and short descriptions.
Disease DOID Description
Alzheimer’s Disease (AD) DOID:10652 Tauopathy, characterized by memory lapses, emotional instability
and progressive loss of mental ability. It results in progressive
memory loss, impaired thinking, changes in personality and mood,
up to profound decline in cognitive and physical functioning.
Attention Deficit Hyperac-
tivity Disorder (ADHD)
DOID:1094 Specific developmental disorder, characterized by co-existence of
attentional problems and hyperactivity.
Autistic Disorder DOID:12849 An autism spectrum disorder, characterized by symptoms across
three symptom domains (communication, social, restricted repeti-
tive interests and behaviors) and delayed language development.
Bipolar Disorder DOID:3312 A mood disorder that involves alternating periods of mania and
depression.
Major Depressive Disorder
(MDD)
DOID:1470 An endogenous depression that is characterized by an all-
encompassing low mood accompanied by low self-esteem, and by
loss of interest or pleasure in normally enjoyable activities.
Parkinson’s Disease (PD) DOID:14330 Synucleinopathy, based on the degeneration of the central nervous
system that often impairs motor skills, speech, and other functions.
Schizophrenia DOID:5419 Psychotic disorder, characterized by a disintegration of thought
processes and of emotional responsiveness.
Onto Suite Miner [136] was used to obtain all genes linked to the DO IDs from the 863
databases supplying gene–disease association information (GeneRIF, OMIM and 864
EnsemblVariation). The various databases have different approaches to disease-gene 865
annotations. EnsemblVariation relies on genetic mutations (mostly Single Nucleotide 866
Polymorphisms, SNPs), whereas OMIM and GeneRIF contain curated text annotations 867
describing disease–gene associations. These can be queried with text-mining tools and 868
data can be extracted. The different sources were considered individually and jointly. 869
All presented results refer to the full set of disease associated genes irrespective of the 870
original data source. The number of genes linked to each of the diseases can be seen in 871
row: “Disease Genes” in Table 7. 872
Since not all disease genes are expressed in the synapse, we used the synaptic 873
proteome (Section “Comparison with proteomic data”) to filter the disease associated 874
genes for genes that are expressed in the synapse (see row: “Disease genes in the 875
synapse”, Table 7). Since almost all modelled genes are expressed in the synapse we 876
only present numbers describing the overlap between disease proteins found in the 877
synapse and modelled genes (see row “Disease Genes in Synapse and in Modelled 878
Genes”, Table 7) 879
There seem to be large differences in the number range of genes associated with 880
diseases. However, the proportions of genes associated with a disease and expressed in 881
the synapse range between 33% (Bipolar Disorder and Major Depressive Disorder) and 882
45% (Schizophrenia). When looking at the overlap of modelled genes and 883
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Table 7. Overlap of modelled and disease genes.
Disease AD ADHD Autistic
Disor-
der
Bipolar
Disor-
der
MDD PD Schizo-
phre-
nia
Disease Genes 1511 665 575 1140 616 620 1844
Disease Genes in the Synapse 645 (43%) 233 (35%) 255 (44%) 379 (33%) 202 (33%) 262 (42%) 828 (45%)
Disease Genes in Synapse and
in modelled Genes
63 (9.8%) 20 (8.6%) 30
(11.8%)
45
(11.9%)
23
(11.4%)
16 (6.1%) 92
(11.1%)
Overlap of modelled and disease genes and their presence in the synapse and our modelled gene set. Disease information is
based on GeneRif, OMIM and EnsemblVariation database data. “AD” stands for Alzheimer’s Disease, “ADHD” for Attention
Deficit Hyperactivity Disorder and “PD” for Parkinson’s Disease. Numbers in brackets refer to the percentages. Percentages
in the “Disease Genes in the Synapse” column are relative to the total of “Disease Genes” and “Disease Genes in Synapse and
in Modelled Genes” is relative to the number of “Disease Genes in Synapse”.
disease-associated genes (in the synapse) numbers vary. Schizophrenia seems to have 884
the highest net overlap (92 genes), but also shows the highest number of total 885
associated genes (1844). In total, between 6.1% (Parkinson’s Disease) and 11.8% 886
(Autistic Disorder) of disease genes associated with any of the selected diseases 887
expressed in the synapse appeared in at least one model. 888
Table 8. Modelled genes associated with three or more of the selected diseases.
GeneNames ADHD AD Autistic
Disor-
der
Bipolar
Disor-
der
MDD Schizo-
phre-
nia
PD
CACNA1C, DRD2, GRIN2A, GRIN2B 1 1 1 1 1 1 1
GRM5 1 1 1 1 0 1 1
CACNB2, DRD1 1 1 1 1 1 1 0
HOMER1 0 1 1 0 1 1 1
CACNA1S, GRM7 1 0 1 1 1 1 0
NOS1 1 1 0 1 0 1 1
GNB3, GRM2 0 1 0 1 1 1 0
GRIA2 0 1 1 0 1 1 0
GNAL 1 0 0 1 1 1 0
PLA2G6 0 0 0 1 0 1 1
ATP2A3, CACNA2D1, GRM3 0 0 0 1 1 1 0
GRIK2, GRM8, GRIP1, PPP1R1B 0 0 1 1 0 1 0
DLG4, NRGN 0 1 0 0 0 1 1
GRIA4 0 1 0 0 1 1 0
FYN, GRIA1, GRIN1, GRM1, GNB2L1 0 1 0 1 0 1 0
SHANK3 1 0 1 0 0 1 0
We were also interested in synaptic genes common to a number of diseases. Table 8 889
shows the 32 synaptic genes linked to three or more of the diseases included in the 890
analysis. Seven genes are associated to six or all seven tested diseases. The top coverage 891
disease associated genes, found in models annotated, include the protein family 892
voltage-dependent calcium channel family CACNA1C and CACNB2 and dopamine D1 893
and D2 receptors (DRD1, DRD2 ), the inotropic glutamate NMDA receptors, type 894
subunit 2A and 2B (GRIN2A, GRIN2B) as well as the glutamate metabotropic receptor 895
5 (GRM5). Of the set of modelled genes, 130 (around 50% of the total) are not 896
associated with any of the seven diseases. 897
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In summary, the fraction of genes modelled is relatively small and might indicate 898
that it is challenging to use existing models to make disease predictions. On the other 899
hand the modelled genes can be starting points to extend models to obtain better 900
disease insights, as will be considered later (Approaches to including non-modelled 901
disease genes in models). 902
Family trees of entities 903
Our identification of entities in models makes it possible to query in which models a 904
particular entity is contained. The mapping of entities to genes allows querying models 905
by genes that are, or may be, modelled. It is also desirable to query models by families 906
of molecules. For example Gutierrez-Arenas et al. [18] and Nair et al. [17] include 907
PDE4A, whereas Kim et al. [30] and Oliveira et al. [28] include PDE4B in their models, 908
and Kim et al. [21] and Qi et al. [19] specify PDE4. It would be desirable to be able to 909
search for models containing any of the PDE4 subfamily of genes. 910
To enable query by class or family, we determined 29 hierarchical family trees of 911
“proteins”, “protein families” and “protein multimers” implied by the sets of genes 912
corresponding to each (Fig 10). Each “protein family” or “protein multimer” entity is 913
the parent to one or more “proteins” or “protein families”. Each child corresponds to a 914
subset of the proteins in the parent. Tree structures were generated for all “protein 915
multimers” and for “protein families” where a member of that family has been modelled 916
explicitly in at least one of our analysed models. This meant that, for example, PP1 is 917
not represented, since none of its children PPP1CA, PPP1CB and PPP1CC appear in 918
any model explicitly. Individual proteins appear only if they are part of a family or 919
multimer, and they appear in a model – thus, for example, GRIA4 and GRIN3 do not 920
appear. Proteins that do not belong to a family, e.g. PSD95 (DLG4 ), are not shown. 921
Any entity that is part of a family can be mapped to the root node of its tree. 922
Entities that do not belong to a family are implicitly their own root. This mapping of 923
“entities to entity families” (Fig 3) can be applied to the model-entity catalogue (Fig 4) 924
to give the simplified summary mapping of models to 104 family roots shown in Fig 11. 925
This facilitates comparison of entities across models trying to address the differences in 926
model detail between models. 927
Frequency of modelling 928
To give an indication of which are the frequently modelled entities and families of 929
entities, we determined the number of models in which each of the root entities in 930
Fig 12 appears (Table 9). About 50% of root entities appear only in one model. In 931
total, 26 (about 25%) of the entity roots were included in five models or more. The 932
three most frequently modelled entities and families are CaM, CaMKII and Ca, which 933
are included in 18, 22 and 23 out of 30 analysed models respectively. This is due to a 934
number of models focusing specifically on the Ca–CaM–CaMKII pathway or including it 935
as a model part, reflecting its central role in synaptic biology. These top coverage 936
families are followed by families such as PP3 and PP1, PKA and PPP1R, which are also 937
included in the models that include the phosphorylation-dephosphorylation circuit 938
(Section “Models of hippocampal synaptic signalling pathways”). Receptor related 939
families such as AMPAR appear with lower frequency, reflecting the fact that, while 940
crucial for synaptic physiology, not all models include them as a readout mechanism for 941
LTP and LTD. Even though our coverage of models is not complete, it seems likely that 942
cataloguing further models will not change the order much. 943
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Fig 10. Family trees of “protein families” and “protein multimers”. “Proteins” are shown in italics; “protein
families” and “protein multimers” in roman. “Proteins” that do not belong to any family are not shown. Only proteins that
are specified in models are shown.
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Fig 11. Summary mapping of entities in models. The occurrence of an root
entity in a model is indicated by open circles. Lower-level entities are folded into their
root entity.
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Table 9. Numbers of entities or entity families found in models.
Entity family Models Frequency % Frequency
2AG, actin, ACTN, Adn, AKAP, AKAR3, CaMKIV, CaMKK,
cGMP, CHRM4, cortactin, CRH, CRHR, CSK, DAGL, DGK, DNM,
GKAP, GRIK2, Homer, IRSP53, KALRN, LYN, NO, NOS, PAK1,
PEBP1, PICK1, PSD93, PSD95, PTPN11, PTPRA, RAC1, RAC2,
RACK1, RAP1GAP, RHOC, RHOG, SAP102, Shank, SHC, SOS,
Spectrin, SRC, STEP, SYNGAP1
1 46 47.4
APC, CK1, FYN, GRB2, IP3R, PI3K, PIP2, PVALB, RASA1,
RASGRF, SAP97, SERCA
2 12 12.4
AA, DAG, GRIP1, Mg, Ng, RAS, VGCC 3 7 7.2
CDK5, DUSP, Glu, GTP, IP3, PLA2 4 6 6.2
DA, DRD, mGluR, NCX, PLC, PMCA 5 6 6.2
CB, NMDAR 6 2 2.1
ATP, MAP2K, MAPK, Raf 7 4 4.1
cAMP, Gabg, PKC, PP2 9 4 4.1
AC 10 1 1.0
AMPAR, PDE 12 2 2.1
PPP1R 14 1 1.0
PKA 15 1 1.0
PP1 16 1 1.0
PP3 17 1 1.0
CaM 18 1 1.0
CaMKII 22 1 1.0
Ca 23 1 1.0
“Models” is the number of models containing the entity or at least one member of the family. “Frequency” is the number of
appearances of the family or entity in the given number of models, and “% Frequnecy” is the frequency expressed as a
percentage.
Comparing models based on their entities 944
Having annotated the models with entities enabled us to compare models with each 945
other by applying a hierarchical clustering approach to the model-entity root mapping 946
(Fig 11). Ward’s 2D method, as implemented in R’s hclust function was used to give 947
the dendrogram shown in Fig 12. We also applied the clustering to the full model-entity 948
matrix (Fig 4), with similar results, though slightly less meaningful groupings. 949
In Fig 12 similar models cluster together. Three models (Byrne et al. [58], Pepke et 950
al. [20] and Stefan et al. [59]) are clustered together as they all contain the identical set 951
of entities: Ca, CaM and CaMKII. The closely related model of Zeng and Holmes [27] 952
includes CB as well, and the closely related models of Miller et al. [49] and Khan et 953
al. [32] are also centred on CaMKII. The related models of Smolen et al., 2006 [100] and 954
Smolen et al., 2012 [16] feature the MAPK pathway, in addition to CaMKII. 955
The group of models containing Li et al. [33], Graupner and Brunel [22], Mattioni 956
and Le Nove`re [34] and Zhabotinsky et al. [83] are all variations on the CaMKII 957
phosphorylation-dephosphorylation circuit, all adding PP1 and PP3 (calcineurin) to the 958
Ca–CaM-CaMKII pathway. All the models so far are hippocampal; Kim et al. [31] is 959
the closest related striatal model to those mentioned. The model of Sorokina et al. [23] 960
is dissimilar to other models, reflecting the large number of entities, particularly 961
scaffolding proteins, which are contained in this model but not in others. 962
The next cluster contains a sub-cluster of mostly striatal models [15,17–19,21,30], 963
with the exception of Castellani et al. [82], which is one of the few hippocampal models 964
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Gutierrez−Arenas et al. (2014)
Nakano et al. (2010)
Nair et al. (2015)
Qi et al. (2010)
Oliveira et al. (2010)
Kim et al. (2010)
Kötter (1994)
Oliveira et al. (2012)
Castellani et al. (2005)
Kim et al. (2011)
Sorokina et al. (2011)
Zhabotinsky et al. (2006)
Mattioni and Le Novère (2013)
Graupner and Brunel (2007)
Li et al. (2012)
Smolen et al. (2006)
Smolen et al. (2012)
Castellani et al. (2001)
Hernjak et al. (2005)
Zeng and Holmes (2010)
Stefan et al. (2008)
Byrne et al. (2009)
Pepke et al. (2010)
Khan et al. (2011)
Miller et al. (2005)
Antunes and De Schutter (2012)
Antunes et al. (2016)
Bhalla and Iyengar (1999)
Kim et al. (2013)
Kuroda et al. (2001)
Fig 12. Clustering of model-entity family root matrix. Clustering as
implemented in R’s hclust function with the Ward.2D method.
to contain the AC–cAMP–PKA pathway as well as hydrolisation of cAMP to AMP by 965
PDE. The model of Bhalla and Iyengar contains these pathways and many more, 966
accounting for its loose connection with this cluster. In summary, we have shown that 967
models the entity composition can be used to the similarities between models. 968
Approaches to including non-modelled disease genes in models 969
Knowing which disease associated genes are included in models helps models with high 970
potential to explain disease impact on the synapse to be identified (“Modelled genes 971
and their overlap with disease genes”). It also allows us to identify disease associated 972
proteins which do not appear in the models we analysed. Of all disease associated genes, 973
1,248 are found in the synaptic proteome but not in any of the analysed models. 974
Table 10 shows the 32 genes that are associated with 5, 6 or all 7 diseases, and which do 975
not appear in any of the investigated models. Of these, COMT and SLC6A3 are 976
associated with all 7 diseases of interest. Since these genes are associated with all or 977
many studied diseases, they could be of interest when it comes to gaining a better 978
understanding of generic disease dysfunctions. 979
Supporting the idea that genes implicated in many diseases could be potentially 980
targets for modelling, we identified two genes, COMT and MAOA, that have been 981
included in metabolic models [137,138]. Functionally, the catechol O-methyltransferase 982
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(COMT ) degrades catechols, such as dopamine, by catalysing their methylation. This 983
methylation results in one of the major degradative pathways of the catecholamine 984
transmitters [139]. Dopamine is included in a number of analysed models [140,141], and 985
it could be possible to explore what happens in these models if there is an excess of 986
dopamine due to COMT malfunction. 987
Table 10. Disease associated genes not appearing in any of the annotated models.
Gene Names ADHD AD Autistic
Disor-
der
Bipolar
Disor-
der
MDD Schizo-
phre-
nia
PD
COMT, SLC6A3 1 1 1 1 1 1 1
GIGYF2 1 0 1 1 1 1 1
GSK3B, ABCB1 1 1 0 1 1 1 1
ANK3, ENO1, KIF5C, MAOA, PRNP,
SLC17A6, CSMD1
1 1 1 1 1 0 1
ACE, GAD1 0 1 1 1 1 1 0
DDC, FMR1 1 0 1 1 0 1 1
APAF1, DFNA5, ELAVL2, GRIK1, HINT1,
ITIH1, ITIH3, ITIH4, STT3A, LIG4, ND-
UFAB1, NDUFB7, NPY, NTRK3, GATB,
SMARCA2, MAD1L1, PRPF3, SH3PXD2A,
TRANK1, PPIF, NT5C2, KIF21B, RPRD2,
SYNE1, NGEF, TENM4, GNL3, MPP6,
MRPS21, RAB39A, CNNM2, OXR1, ANKS1B,
VARS2, AS3MT, PALB2, DCTN5, PPP1R21,
MTPN, SLC39A12, CHSY3
1 0 1 1 1 0 1
CNR1 1 1 0 0 1 1 1
YWHAZ 1 1 1 0 0 1 1
SNAP25 1 1 1 0 1 0 1
CNTNAP2 1 1 1 1 0 0 1
The table only lists genes that are associated to four or more diseases.
Genes associated will all studied diseases could represent generic disease mechanisms, 988
in which case exploring the role of COMT in dopaminergic models would indicate the 989
possible influence of the gene in many diseases. An alternative approach is to consider 990
disease specific genes not appearing in models and associated to only one of the selected 991
diseases. Integrating such proteins into pre-existing models could thus help to gain 992
disease-specific insights. 824 of the disease associated genes are specific to one disease 993
only. To identify genes that can be integrated into existing models, the list of 994
non-modelled disease associated genes was compared with genes in pathways enriched 995
amongst the modelled genes. 996
For example, all disease genes unique to Schizophrenia were compared with the list 997
of genes in pathways significantly enriched amongst the modelled genes, giving a list of 998
8 genes, each of which is found in one or more pathways (Table 11). One of these genes 999
is LAMTOR2. The LAMTOR2:LAMTOR3 complex binds MAPK components [142], 1000
together with other members of the MAPK2 and MAPK activation pathway, such as 1001
RAF1, MAPK1, MAPK3 and MAP2K2. In this role it contributes to the activation of 1002
the MAPK pathway which has a central role in striatal and cerebellar synapses. 1003
Including the influence of LAMTOR2 on the activity of MAPK in a pre-existing model 1004
could hence help to better understand its role and links to and effects on schizophrenia. 1005
Integrating LAMTOR2 activity in the model could be done mechanistically, or 1006
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Table 11. Schizophrenia specific genes not found in models and appearing in pathways that are enriched in
annotated models.
Gene Name Gene Name (long) REACTOME pathway Pathway ID
CCK cholecystokinin G alpha (q) signalling events R-HSA-416476
LAMTOR2 late endoso-
mal/lysosomal adaptor,
MAPK and MTOR
activator 2
MAP2K and MAPK activation, FCERI
mediated MAPK activation, VEGFR2 me-
diated cell proliferation, RAF/MAP kinase
cascade
R-HSA-5674135,
R-HSA-2871796,
R-HSA-5218921,
R-HSA-5673001
PSMB1 proteasome subunit beta
1
FCERI mediated MAPK activation,
VEGFR2 mediated cell proliferation,
RAF/MAP kinase cascade
R-HSA-2871796,
R-HSA-5218921,
R-HSA-5673001
PSMB4 proteasome subunit beta
4
FCERI mediated MAPK activation,
VEGFR2 mediated cell proliferation,
RAF/MAP kinase cascade
R-HSA-2871796,
R-HSA-5218921,
R-HSA-5673001
PSMC1 proteasome 26S subunit
and ATPase 1
FCERI mediated MAPK activation,
VEGFR2 mediated cell proliferation,
RAF/MAP kinase cascade
R-HSA-2871796,
R-HSA-5218921,
R-HSA-5673001
PSMC4 proteasome 26S subunit
and ATPase 4
FCERI mediated MAPK activation,
VEGFR2 mediated cell proliferation,
RAF/MAP kinase cascade
R-HSA-2871796,
R-HSA-5218921,
R-HSA-5673001
PSMD2 proteasome 26S subunit
and non-ATPase 2 and
FCERI mediated MAPK activation,
VEGFR2 mediated cell proliferation,
RAF/MAP kinase cascade
R-HSA-2871796,
R-HSA-5218921,
R-HSA-5673001
TUBB3 tubulin beta 3 class III Chaperonin-mediated protein folding R-HSA-390466
functionally, for example by influencing the MAPK concentration. 1007
Discussion 1008
We have developed a catalogue of genes whose corresponding proteins correspond to 1009
entities in computational models of synaptic plasticity. To achieve this we developed a 1010
new set of standard identifiers for entities in computational models, and mapped those 1011
entities corresponding to proteins and protein families onto genes. Although time and 1012
lack of machine-readable model descriptions constrained the number of models we could 1013
analyse, by selecting models from three brain regions (hippocampus, striatum and 1014
cerebellum) we are confident that we have covered the bulk of proteins in models. 1015
We were able to identify 294 genes that could be mapped to entities in 1016
computational models. This corresponds to 4.2% of the 6,706 known genes in the 1017
synaptic proteome. Enrichment analysis showed that, compared to the set of proteins 1018
found in the synapse, the genes in models tended to have more signalling functions, 1019
which reflects the focus on signalling pathways in such models. This suggests 1020
considerable scope for including new molecules in models. However, models of synapses 1021
at the molecular level are already complex and are beset by problems of determining 1022
parameters. One strategy to prioritise molecules to add to models is to add those most 1023
relevant for disease. Our comparison of the list of genes in models with databases of 1024
gene-disease association shows that many disease-associated genes are not currently 1025
included in synaptic models, and suggests targets for future modelling. 1026
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Targeting disease-relevant proteins for modelling 1027
The genes in models are more associated with neurological diseases, such as 1028
Schizophrenia, Alzheimer’s, Huntington’s disease and bipolar disorder, than randomly 1029
selected genes in the synaptic proteome or the whole genome. Nevertheless, depending 1030
on the disease, the number of disease-associated genes included in models range between 1031
6% and 12% of the disease-associated genes in the synapse. This suggests that there is 1032
considerable potential to include disease-related genes in models. Including these 1033
molecules could make these models more useful in helping elucidate disease mechanisms 1034
and helping to identify new drug targets. 1035
We identified two un-modelled genes associated with 7 neurological diseases, COMT 1036
and MAOA and we found they have close functional links with existing models. By 1037
incorporating pathway enrichment results, we identified LAMTOR, a gene uniquely 1038
associated with Schizophrenia. LAMTOR is linked to the MAP kinase pathway, which 1039
features in a number of existing models. This demonstrates the utility of our approach 1040
for identifying which proteins to incorporate in existing models so that they can make 1041
disease-associated predictions. Further investigation using this approach could indicate 1042
other target proteins to add to existing synaptic pathway models to make them more 1043
informative about the influence of diseases on the synapse. 1044
A new ontology for computational neuroscience models 1045
The challenge we faced mapping model entities to genes highlighted a gap between 1046
bioinformatics, where each gene is well-defined and has a commonly used identifier, and 1047
computational neuroscience, where the elements of models are defined at varying levels 1048
of precision: for example they may be proteins, protein families or multimers of proteins. 1049
Even within the same model, one element may be specified precisely, for example a 1050
particular isoform (PKMζ), and another element may be generic, for example 1051
“plasticity related proteins” [16]. From a bioinformatics perspective this may seem 1052
offensive, but from the viewpoint of computational neuroscience it is entirely valid: a 1053
computational model can be seen as a means to reasoning about a hypothesis; the 1054
formulation of the model is the hypothesis and the simulations embody the reasoning 1055
that generates the predictions arising from the hypothesis [143]. The modelling process 1056
sometimes even requires hypothetical elements, which have no existing identifier. For 1057
example, one seminal computational neuroscience model [144] contained hypothetical 1058
elements (“gating particles”) that predicted essential features of ion channels function. 1059
The problem of mapping model constituents onto biological entities was noted by the 1060
originators of the MIRIAM standard [118]. This standard suggests solving the problem 1061
of mapping entities at different levels of abstraction by using a “HasVersion” qualifier to 1062
map reactants in models to multiple entities, e.g. to map IP3R to Inositol 1063
1,4,5-triphosphate receoptors type 1, 2 and 3. Most of the models we investigated had 1064
not been annotated to MIRIAM standards, and we found it more efficient to define our 1065
own ontology containing proteins and protein families. We found that existing 1066
ontologies such as UniProt, HGNC gene families [145] and Neurolex [146] were not 1067
extensive enough to map proteins specified at different levels of precision (e.g. PDE4A, 1068
PDE4) to common families (e.g. PDE), though HGNC gene families covered about half 1069
of the protein families we identified. 1070
In the absence of a suitable ontology, we used HGNC gene families and curated other 1071
family relationships manually to give a full list of entities (Supporting Information 1072
Tables S1) and mappings of proteins to families and multimers in which they occur 1073
(Supporting Information Tables S3, S4). These tables form the kernel of an ontology, 1074
and we have demonstrated that it can be used to determine the potential genes 1075
underlying the proteins in computational models, and to cross-link these genes with 1076
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expression data. Furthermore, we have demonstrated that the ontology can be used to 1077
compare models, for example using hierarchical clustering, and to summarise of how 1078
often various protein families have been modelled. By annotating models with 1079
identifiers of brain region or neuron type, the set of possible proteins belonging to a 1080
model could be narrowed down according to the genes that are expressed in a given 1081
region. The same procedure could be used to link the genetic content of synaptic 1082
models with other types of data, for example spatial expression data from the Allen 1083
Brain atlas. This would make it possible to check that a particular model was valid in 1084
the brain region it is supposed to represent, or, conversely, could be used to find brain 1085
regions for which a particular model might be valid. 1086
The number of models analysed in this paper was limited by the time it took us to 1087
annotate models we had not constructed. While some repositories, such as the curated 1088
branch of BioModels, enforce curation of models to MIRIAM standards [118], it would 1089
be desirable for all models to be annotated consistently at the time of publication or 1090
deposition in a repository. Annotation would be a fairly quick process for authors 1091
familiar with the models, and the quality of the information would be higher than if 1092
annotated by third parties. Three of the 30 models we investigated were annotated to 1093
MIRIAM standards. We did not use the MIRIAM annotations of these models, partly so 1094
that our annotation of models was consistent and partly because the MIRIAM standard 1095
suggests mapping to external identifiers that are often at a finer level of granularity 1096
than we needed to compare models to proteomic data. Were more models curated to 1097
MIRIAM standards, it would be worthwhile developing a mapping to our identifiers. 1098
As discussed above, some models are of necessity not precise about which protein is 1099
specified. To address this, one option would be for the computational neuroscience and 1100
bioinformatics communities to adopt an ontology along the lines of the ones we have 1101
generated here. If the ontology were stored in the Interlex dynamic lexicon of 1102
biomedical terms, a development of Neurolex [146], it would be straightforward for 1103
authors to suggest new terms or relationships. The model metadata could be stored by 1104
adding fields to existing repository schema, or our data could be converted to a 1105
standalone, API-enabled database. 1106
Nomenclature 1107
The nomenclature we have used for entities has been decided by the authors. We have 1108
been guided by gene names, and some of our choices might be controversial, for example 1109
naming PP2B (calcineurin) PP3. Our rationale for using identifiers related to gene 1110
names is so there is more consistency between the names of members in a family. For 1111
example, in Fig 10, PP3 is the parent of the catalytic and regulatory subunits PPP3C 1112
and PPP3R; having PP2B as a parent would not be equally consistent. It would be 1113
desirable for the computational neuroscience and bioinformatics communities to agree a 1114
common nomenclature. 1115
New directions in modelling 1116
We have demonstrated the potential of our method of identifying entities in models and 1117
mapping them to genes to suggest new, disease-relevant directions for modelling. We 1118
believe there is considerable potential for the work to be adopted to suit the needs of 1119
the community. Our files are available (S1 File) and suggestions for additions or 1120
amendments are welcome. [We will also be making our files available via github.] 1121
More speculatively, despite the challenge of expanding the number and relevant 1122
proteins in models of synaptic plasticity, we believe that the time has come to 1123
incrementally increase the number of proteins involved in models, especially those 1124
involved in disease mechanisms. 1125
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Methods 1126
Identifying entities in models 1127
The question of what entities mean is outlined in “Analysis of proteins in synaptic 1128
models”, subection “Identifying entities in models”. The constituent entities of each 1129
model were identified by one of the authors (EMW, KFH or DCS) reading the paper, or 1130
extracting elements from a machine-readable representation of the model, for example 1131
CellML or Kappa descriptions in the cases of Bhalla and Iyengar [80] and Sorokina et 1132
al. [23] respectively. The name used to identify the entity in the model was then 1133
mapped to the standardised list of entities that we built up as we looked through the 1134
models. In some cases model entities were not specified enough to allow us to map them 1135
unambiguously onto a model entity – for example “Plasticity Related Protein” [16]. We 1136
did not consider a complex as an entity – for example a Ca-CaM-CaMKII complex 1137
would give rise to Ca (ion), CaM (“protein”) and CaMKII (“protein multimer”). In 1138
naming our standard entities, we have tried to use names commonly used in models, but 1139
for entities that have not appeared in many models we have tended to use the newer 1140
standard names that appear in the NCBI or UniProt databases. 1141
Mapping entities to a unique gene identifier 1142
To obtain a common identifier for all entities we searched for an ontology that could be 1143
used to identify our entities, especially “protein families” and “protein multimers”. We 1144
considered a number of potential ontologies: 1145
The Computational Neuroscience Ontology 1146
(http://bioportal.bioontology.org/ontologies/CNO) This ontology covers 1147
the description of the modelling technique (e.g. Integrate-and-fire neurons) rather 1148
than the components of the model. 1149
HGNC Gene families (http://www.genenames.org/) The Human Gene 1150
Organisation Gene Nomenclature Committee (HGNC) approves unique symbols 1151
and names for human genes, and also places genes in families, based on 1152
characteristics such as function, homology, domains and phenotype [145]. Placing 1153
genes into families is a manual process, often involving specialists who are expert 1154
in that family of genes. Often, but not always, genes in the same family have a 1155
common root symbol. The process of defining families is ongoing. 1156
InterPro protein families (http://www.ebi.ac.uk/interpro) The InterPro 1157
Consortium is a federation amalgamating protein signature databases (Gene3D, 1158
Conserved Domain Database, HAMAP, PANTHER, Pfam, PIRSF, PRINTS, 1159
ProDom, PROSITE, SMART, SUPERFAMILY, Structure-Function Linkage 1160
Database and TIGRFAMs) [147]. Protein signatures are predictive models build 1161
on fragments of amino acid sequences that share local features (e.g. conservation 1162
at different positions) known to be associated with a function or structure [148]. 1163
There are multiple computational approaches that are detecting such patterns and 1164
define types of signatures [149]. The similarity in signature matches between 1165
proteins is used to define a hierarchy of families. 1166
Manual NCBI search (www.ncbi.nlm.nih.gov/gene/) The National Center for 1167
Biotechnology Information (NCBI) provides access to biomedical and genomic 1168
information. We used their searchable database of genes, which can be queried 1169
with a number of different identifiers. 1170
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We intended to map out entities using information supplied by one of these 1171
ontologies, but no one source proved sufficient. In InterPro, there are a number of 1172
families that correspond exactly to proteins, for example Phospholipase A2 (IPR001211) 1173
and Phosphoinositide phospholipase C (IPR001192). However, some proteins, including 1174
SOS1 and SOS2, belong to very broad families. 1175
In the HGNC database we identified a relatively large number of our entities that 1176
correspond to existing HGNC gene families. For example the HGNC Homer family 1177
(short for “Homer scaffolding proteins”) comprises the genes HOMER1, HOMER2 and 1178
HOMER3 and the genes PPP3CA, PPP3CB, PPP3CC, PPP3R1 and PPP3R2 belong 1179
to the HGNC PP3 family (short for “Calcineurin”). Other entities do not correspond to 1180
a single gene family, but can be extracted from the database by selecting multiple 1181
families. For example SHANK, by which we mean the family of proteins encoded by 1182
SHANK1, SHANK2 and SHANK3 may be selected from the gene families list by 1183
selecting all genes that are in the “Ankyrin repeat domain containing” (ANKRD) and 1184
“PDZ domain containing” (PDZ) gene families. Some of our entities cannot be recovered 1185
by searching for families. For example SOS (by which we mean the proteins encoded by 1186
SOS1 and SOS2 ) are in both the “Rho guanine nucleotide exchange factors” and 1187
“Pleckstrin homology domain containing” families, but so are 35 other proteins. 1188
We also curated our own mappings by manually querying the NCBI portal by 1189
searching for human genes matching a full protein name and a common gene prefix, 1190
suffix or infix, if available. For example, Entrez IDs for a “protein family” of 1191
Voltage-dependent calcium channel were obtained with the following query: 1192
‘Voltage-dependent calcium channel[All Fields] AND CACN*[All Fields] AND ”Homo 1193
sapiens”[Organism]’. The top 20 results were considered and only entries with the 1194
closest description and gene summary to the search term were extracted. 1195
Although we were not able to map all our entities by relying on only one ontology, 1196
we found that HGNC families covered more of our entities than Interpro, so we used 1197
this as a basis for developing an ontology to describe the molecular components of 1198
computational neuroscience models. We tried to map all entities of type “protein family” 1199
and “protein multimer” to HGNC families. Manual NCBI mappings were used to check 1200
and verify that HGNC families represented the modelled group of genes. 1201
In situations where we were unable to find a corresponding HGNC family we (1) 1202
suggested some protein groups to be added to the list of HGNC families and await 1203
approval of the request; (2) we had no choice but to fall back on our manual NCBI 1204
mapping. The combination of the above lead us to our final mappings. S3 Table and S4 1205
Table show identified HGNC families as well as the genes belonging to them. The 1206
superscript given with the HGNC family name indicates its origin, the official HGNC 1207
mapping vs. custom mapping. The columns “IN.SYNAPSE” and “OUT.SYNAPSE” 1208
are explained in Section “Comparison with proteomic data”. 1209
Enrichment Analysis 1210
A commonly used method to find statistically significant commonalities between large 1211
gene lists is enrichment analysis, also known as over-representation analysis. Based on 1212
information contained in ontological databases, enrichment analysis can show if a set of 1213
“genes of interest” contains a significantly high number of genes with the same 1214
annotation. This approach allows us to gain a better understanding of underlying 1215
common themes in our “genes in models” list. 1216
The underlying principle of such an enrichment analysis is to estimate, for each 1217
specific category annotated in the database of interest, if the number of genes in our 1218
genes of interest set associated with a certain category is larger than expected by chance. 1219
To test this relationship statistically, the hypergeometric distribution or one-tailed 1220
Fisher’s exact test is commonly applied. Both are known to be equivalent [150]. 1221
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The four key numbers required to carry out the statistical calculations are: 1222
1. The number of elements in the full dataset, also considered as the background 1223
dataset, N . In our case these are all proteins part of the synaptic proteome. 1224
2. The number of elements n in the subset of the full dataset which is tested for 1225
enrichment. This is the number of genes in the “genes in models” list. 1226
3. The number of elements associated to a certain trait in the full dataset, T . It 1227
corresponds to the set of genes annotated to any term in one of the databases, e.g. 1228
“Schizophrenia”, which describes a disease in the DO database. 1229
4. The subset of n shared by the elements found in T , denoted as t. This refers to 1230
the number of genes within a category that are also present in our “genes in 1231
models” list. 1232
The probability of encountering the exact number of hits t of interest given N , n and T 1233
is calculated with the hypergeometric probability h(t;N,n, T ): 1234
h(t;N,n, T ) =
(
T
t
)(
N−T
n−t
)(
N
n
) (1)
To describe the probability of finding greater than or equal to the number of items of 1235
interest t, we use the cumulative hypergeometric probability: 1236
p(t;N,n, T ) =
T∑
x=t
h(x;N,n, T ) =
T∑
x=t
(
T
x
)(
N−T
n−x
)(
N
n
) (2)
If this probability is less than a criterion (e.g. p < 0.01), the dataset is regarded as 1237
enriched [150] for the tested category. 1238
For the analysis, ontology terms for all genes in the background dataset N were 1239
obtained. Initially two background sets were considered, containing (1) all genes in the 1240
genome and (2) all proteins found in the synapse. Since results were quite similar and 1241
the focus of this study is on the synaptic region rather than the whole organism, we 1242
only present results obtained with the second dataset as the background set of genes. 1243
We analysed all terms that had at least one gene associated to our “genes in models”. 1244
For each such term, the p-value was calculated, indicating potential enrichment, and 1245
then corrected for multiple comparison, using the Benjamini and Yekutieli [151] method. 1246
Terms with adjusted p-values smaller than 0.01 are presented in the final results. 1247
topONTO and topGO 1248
Ontologies that supply functional annotation information are organised in a hierarchical 1249
structure, with the most generic terms at the top, and the most specific ones at the 1250
bottom. The higher the term is located in the hierarchy, the more genes are associated 1251
to it as it aggregates all genes from its child terms. Hence, a single gene can be found 1252
on different levels of annotation specificity. Depending on the purpose of the analysis it 1253
is important to be able to choose the level of retrieved terms. 1254
To retrieve the most specific and refined terms among significantly enriched ones, we 1255
used an algorithm proposed by Alexa et al. [152] and implemented for the GO database 1256
by the R topGO package. Since GO is represented as a Directed Acyclic Graph (DAG), 1257
the authors incorporated the underlying GO graph topology in the term scoring 1258
approach, removing strong correlations commonly occurring between high level terms. 1259
This allows the enrichment of a very generic term to be ignored, and less frequent but 1260
more specific and potentially more interesting low level ones to be identified. 1261
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Assuming that a child term is potentially more interesting than its more generic 1262
ancestors, significance of a term is calculated depending on its child terms. Out of 1263
multiple versions implementing this idea, we used the elim algorithm paired with 1264
Fisher’s exact test. The decision was based on the clear number of comparisons 1265
conducted by the algorithm. This number was further used to correct for the false 1266
discovery rate. 1267
In the elim approach [152], enrichment analysis starts at the bottom of the ontology 1268
graph. If a child term is significantly enriched amongst the genes of interest, this 1269
influences the number of genes annotated to its ancestor terms. All genes associated to 1270
the enriched child term are removed from the ancestor terms leaving most specific ones 1271
with the minimal indicated significance. 1272
We discovered that the algorithm leads to more refined results than a set-based 1273
enrichment analysis that ignores the ontology structure. Therefore, we were interested 1274
in applying a same approach to other gene annotation sets. This can be achieved with 1275
the topOnto R package [135]. It extends the advantage of the Alexa et al. method to 1276
any hierarchically structured dataset. Since both REACTOME and DO satisfy this 1277
requirement, we were able to apply the same approach to all chosen annotation sets. 1278
Supporting information 1279
S1 File. Data and code. A zip file containing the data tables, and mapping and 1280
analysis code that will reproduce the results in this paper. 1281
S1 Table. Full list of entities. List of entities containing the ID, name, type and 1282
for proteins, mapping to gene. 1283
S2 Table. Synaptic Proteome Studies. List of synaptic proteome publications 1284
and respective datasets used in this study. 1285
S3 Table. Protein family members. List of entities in distinct protein families - 1286
“in” and “out” of the synapse. 1287
S4 Table. Protein multimer members. List of entities in distinct protein 1288
multimers - “in” and “out” of the synapse. 1289
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